Journal Publications

356. Wheatley AK, Pymm P, Esterbauer R, Dietrich MH, Lee WS, Drew D, Kelly HG, Chan LJ, Mordant FL, Black KA, Adair A, Tan HX, Juno JA, Wragg KM, Amarasena T, Lopez E, Selva KJ, Haycroft ER, Cooney JP, Venugopal H, Tan LL, O’Neill M, Allison CC, Cromer D, Davenport MP, Bowen RA, Chung AW, Pellegrini M, Liddament M, Glukhova A, Subbarao K, Kent SJ*, Tham WH*. Landscape of human antibody recognition of the SARS-CoV-2 spike. Cell Reports 2021 In press

355. Cromer D, Khoury DS, Steain M, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Kent SJ, Triccas JA, Davenport MP. In vitro neutralization levels and protection from SARS-CoV-2 variants. Medrxiv pre-print

354. Selva KJ, Davis SK, Haycroft ER, Lee WS, Lopez E, Reynaldi A, Davenport MP, Kent HE, Juno JA, Chung AW, Kent SJ. Tear antibodies to SARS-CoV-2: implications for transmission. Medrxiv pre-print

353. Chaurasia P, Nguyen THO, Rowntree LC, Juno JA, Wheatley AK, Kent SJ, Kedzierska K, Rossjohn J, Petersen J. A structural basis underpinning biased T cell receptor recognition of an immunodominant HLA-A2 restricted epitope from the SARS-CoV-2 spike protein. J Biol Chem 2021 In press

352. Hensen L, Nguyen THO, Rowntree LC, Damelang T, Koutsakos M, Aban M, Hurt A, Harland K, Auladell M, Everitt A, Blacker C, Oyong D, Loughland J, Webb J, Wines B, Hogarth PM, Flanagan K, Plebanski M, Wheatley AK, Chung AW, Kent SJ, Miller A, Clemens B, Nelson J, Davies J, Tong S, Kedzierska K.Robust and prototypical immune responses towards influenza vaccines in the high-risk group of Indigenous Australians. PNAS 2021 In press

351. Li S, Ju Y, Zhou J, Noi KF, Mitchell AJ, Zheng T, Kelly HG, Kent SJ*,Porter CJH*, Caruso F*. Quantitatively Tracking Bio-Nano Interaction of Metal-Phenolic Nanocapsules by Mass Cytometry. ACS Applied Materials & Interfaces

350. Parsons MS, Kristensen AB, Selva KJ, Lee WS, Amarasena T, Esterbauer R, Wheatley AK, Bavinton B, Kelleher AD, Grulich A, Khoury G, Juno JA, Kent SJ. Impact of semen exposure on the efficacy of anti-HIV broadly neutralizing antibody PGT121. Ebiomedicine 2021 In press

349. Lemke MM, McLean MR, Lee CY, Lopez E, Wines BD, Hogarth PM, Worlberg P, Kirschner DE, Kent SJ, Chung AW, Arnold KB. A personalized systems approach to evaluate antibody-Fc receptor activation post RV144 vaccination reveals a limited benefit of increasing IgG1 concentration. Cell Reports Medicine 2021 In press

348. Aitken EH, Damelang T, Ortega-Pajares A, Alemu A, Hasang W, Dini S, Unger H, Ome-Kaius M, Nielsen MA, Salanti A, Duffy P, Narum D, Smith J, Kent SJ, Hogarth PM, Wines BD,Simpson J, Chung AW, Rogerson SJ. Developing a multivariate prediction model of antibody features associated with protection from placental malaria. eLife 2021;10:e65776 DOI: 10.7554/eLife.65776

347. Phetsouphanh C, Darley D, Howe A, Munier CML, Patel SK, Juno JA, Burrell LM, Kent SJ, Dore GJ, Kelleher AD, Matthews G. Immunological dysfunction persists for 8 months following initial mild-moderate SARS-CoV-2 infection. Medrxiv preprint

346. Song J,Ju Y,Amarasena TH,Lin Z, Mettu S, Zhou J, Rahim M, Ang CS, Cortez-Jugo C, Kent SJ*, Caruso F*.Influence of Poly(ethylene glycol) Molecular Architecture on Particle Assembly and Ex Vivo Particle-Immune Cell Interactions in Human Blood. ACS Nano 2021

345. Weiss ACG, Shirbin SJ,Kelly HG,Kent SJ*, Qiao GC*. Plasma proteins reduce human immune cell association of structurally nanoengineered antimicrobial peptide polymers. ACS Applied materials & interfaces. 2021

344. Pilkington E, Suys E, Trevaskis N, Wheatley AK, Danijela Zukancic D, Algarni A, Al-Wassiti H, Davis TP, Pouton C*, Kent SJ*, Truong NP*. From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases. Acta Biomaterialia 2021

343. Leiske MN, Lai M,Amarasena T, Davis TP, Thurecht KJ, Kent SJ*, Kempe K*. Interactions of core cross-linked poly(2-oxazoline) and poly(2-oxazine) micelles with immune cells in human blood. Biomaterials 2021;274:120843 doi.10.1016/j.biomaterials.2021.120843

342. Rowntree LC, Petersen J, Juno JA, Chaurasia P, Wragg K, Koutsakos M, Hensen L, Wheatley AK, Kent SJ, Rossjohn J, Kedzierska K, Nguyen THO. SARS-CoV-2-specific CD8T-cell responses and TCR signatures in the context of a prominent HLA-A*24:02 allomorph. Clinical and Translational Immunology 2021 doi.10.1111/imcb.12482

341. Finnegan JR, Pilkington EH, Alt K,Rahim MA,Kent SJ, Davis TP, Kempe K. Stealth Nanorods for Biomedical Applications via the Aqueous Living Crystallisation-Driven Self-Assembly of Poly(2-oxazoline)s. Chemical Science 2021;12:7350-60

340. Fulford TS, Van H, Gherardin NA, Zheng S, Ciula M, Drummer HE, Redmond S, Tan HX, Center RC, Li F, Grimley S, Wines BD, Nguyen THO, Mordant F, Rowntree L, Cheng AC, Doolan D, Bond K, Hogarth PM, McQuilten Z, Subbarao K, Kedzierska K, Juno JA, Wheatley AK, Kent SJ, Williamson DA, Purcell DF, Anderson D, Godfrey DI. A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2. Medrxiv preprint

339. Lopez E, Haycroft ER, Adair A, Mordant FL, O’Neill M, Pymm P, Redmond S, Gherardin NA, Wheatley AK, Juno JA, Selva KJ, Davis S, Harty L, Purcell DFJ, Subbarao K, Godfrey DI, Kent SJ, Tham WH, Chung AW. Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay. JCI Insight

338. Cromer D, Juno JA, Khoury D, Reynaldi A, Wheatley AK, Kent SJ*, Davenport MP*. Prospects for durable immune control of SARS-CoV-2 and prevention of re-infection. Nature Reviews Immunology 2021 DOI 10.1038/s41577-021-00550-x

337. Nguyen THO, Rowntree L, Petersen J, Chua B, Helsen L, Kedzierski L, Van de Sandt C, Chaurasia P, Tan HX, Habel J, Wu, Allen L, Earnest L, Mak KY, Juna JA, Wragg K, Mordant F, Amanat F, Krammer F, Doolan D, Flanagan K, Sonda S, Kaur J, Wakim L, Westall G, Mannering S, James F, Mouhtouris E, Gordon C, Homes N, Simbert L, Trubiano J, Cheng A, Harcourt P, Clifton P, Wheatley AK, Kent SJ, Rossjohn J, Torresi J, Kedzierska K. High precursor frequency and promiscuity in alpha-beta T cell receptor pairing within CD8+ T-cell responses to an immunodominant SARS-CoV-2 nucleocapsid epitope. Immunity 2021

336. Pymm P, Adair A, Chan LJ, Cooney J, Mordant F, Allison C, Lopez E, Haycroft E, O’Neill MT, Tan LL, Dietrich MH, Drew D, Doerflinger M, Dengler MA, Scott NE, Wheatley AK, Gherardin NA, Venugopal H, Cromer D, Davenport MP, Pickering R, Godfrey DI, Purcell DFJ, Kent SJ, Chung AW, Subbarao K, Pellegrini M, Glukhova A, Tham WH. Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice. PNAS 2021

335. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Kent SJ, Triccas JA, Davenport MP. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature Medicine 2021

334. Wheatley AK, Juno JA, Wang JJ, Selva KJ, Reynaldi A, Tan HX, Lee WS, Wragg KM, Kelly HG, Esterbauer R, Davis SK, Kent HE, Mordant FL, Schlub TE, Gordon DL, Khoury DS, Subbarao K, Cromer D, Gordon TP, Chung AW, Davenport MP, Kent SJ. Evolution of immunity to SARS-CoV-2. Nature Communications 2021

333. Vu MN, Kelly HG, Tan HX, Juno JA, Esterbauer R, Davis TP, Truong NP, Wheatley AK, Kent SJ. Hemagglutinin Functionalized Liposomal Vaccines Enhance Germinal Center and Follicular Helper T Cell Immunity. Advanced Healthcare Materials. 2021

332. Tan HX, Lee WS, Wragg KM, Nelson C, Esterbauer R, Kelly HG,  Amarasena T, Jones R, Starkey G, Wang BZ, Yoshino O, Tiang T, Grayson ML, Opdam H, D’Costa R, Vago A, The Austin Liver Transplant Perfusionist Group, Mackay LK, Gordon CL, Wheatley AK, Kent SJ, Juno JA. Adaptive immunity to human coronaviruses is widespread but low in magnitude. Clinical and Translational Immunology 2021

331. Koutsakos M, Rowntree LC, Hensen L, Chua BY, van de Sandt CE, Habel JR, Zhang W, Jia X, Kedzierski L, Ashhurst TM, Putri GH, Marsh-Wakefield F, Read MN, Edwards DN, Clemens EB, Wong CY, Mordant FL, Juno JA, Amanat F, Audsley J, Holmes NE, Gordon CL, Smibert OC, Trubiano JA, Hughes CM, Catton M, Denholm JT, Tong SY, Doolan DL, Kotsimbos TC, Jackson DC, Krammer F, Godfrey DI, Chung AW, King NJ, Lewin SR, Wheatley AK, Kent SJ, Subbarao K, McMahon J, Thevarajan I, Nguyen TH, Cheng AC, Kedzierska K. Integrated immune dynamics define correlates of COVID-19 severity and antibody responses. Cell Rep Med. 2021:100208.

330. Damelang T, Aitken EH, Killian M, Hasang W, Lopéz E, Unger H, Ome-Kaius M, Umbers AJ, Salanti A, Narum DL, Duffy PE, Kent SJ, Rogerson SJ, Chung AW. Antibody-mediated activation of Natural Killer cells in pregnant women with malaria. Scientific Reports 2021 11;4130

329. Rowntree LC, Chua BY, Nicholson S, Koutsakos M, Hensen L, Douros C, Selva KJ, Mordant FL, Wong CY, Habel JR, Zhang W, Jia X, Allen L, Doolan DL Jackson DC, Wheatley AK, Kent SJ, Amanat F, Krammer F, Subbarao K, Cheng AC, Chung AW, Catton M, Nguyen THO, van de Sandt CE, Kedzierska K. Robust correlations across six SARS-CoV-2 serology assays detecting distinct antibody features. Clinical and Translational Immunology 2021;10:e1258.

328. Lee WS, Selva KJ, Davis SK, Wines BD, Reynaldi A, Esterbauer E, Kelly HG, Haycroft ER, Tan HX, Juno JA, Wheatley AK, Hogarth PM, Cromer D, Davenport MP, Chung AW, Kent SJ. Decay of Fc-dependent antibody functions after mild to moderate COVID-19. Cell Reports Medicine 2021

327. Patel SK, Juno JA, Lee WS, Wragg KM, Hogarth PM, Kent SJ*, Burrell LM*.Plasma ACE2 activity is persistently elevated following SARS-CoV-2 infection: implications for COVID-19 pathogenesis and consequences. European Respiratory Journal 2021:2003730.

326. Seddiki N, Zaunders J, Phetsouphanh C, Brezar V, Xu Y, McGuire HM, Bailey M, McBride K, Hey-Cunningham W, Munier CML, Cook L, Kent SJ, Lloyd A, Cameron B, Fazekas de St Groth B, Koelsch K, Danta M, Hocini H, Levy Y, Kelleher AD. CD73+  CD127high long-term memory CD4 T cells are highly proliferative in response to recall antigens and are early targets in HIV-1 infection. International Journal of Molecular Sciences 2021

325. Jiang W, Wong J, Tan HX, Kelly HG, Whitney PG, Barr I, Layton DS, Kent SJ, Wheatley AK, Juno JA. Screening and development of monoclonal antibodies for identification of ferret T follicular helper cells. Scientific Reports 2021;11:1864.

324. Sutton HJ, Aye R, Idris A, Vistein R, Nduati E, Kai O, Mwacharo J, Li X, Gao X, Andrews TD, Koutsakos M, Nguyen THO, Nekrasov M, Milburn P, Ethala A, Berry A, Natasha KC, Chakravarty S, Sim BKL, Wheatley AK,Kent SJ, Hoffman SL, Lyke K,Bejon P, Luciani F, Kedzierska K, Seder RA, Ndungu FM, Cockburn IA.Atypical B cells are a normal component of immune responses to vaccination and infection in humans. Cell Reports 2021;34:108684.

323. Li Z, Khanna M, Grimley SL, Ellenberg P, Gonelli C, Lee WS, Amarasena TH, Kelleher AD, Purcell DFJ, Kent SJ*, Ranasinghe C*.Mucosal IL-4R antagonist adjuvanted HIV vaccination strategy with SOSIP-gp140 booster can induce sustained high quality cytotoxic CD4+/CD8+ T cells and humoral responses in pigtail macaques. Scientific Reports 2020;10:22077

322. Ju Y, Kelly HG, Dagley L, Reynaldi A, Schlub T, Spall S, Bell C, Cui J, Mitchell A, Lin X, Wheatley AK, Thurecht K, Davenport MP, Webb A, Caruso F, Kent SJ. Person-Specific Biomolecular Coronas Modulate Nanoparticle Interactions with Immune Cells in Human Blood. ACS Nano 2020;14:15723-15737

321. Jiang W, Pilkington EH Kelly HG, Tan HX, Juno JA, Wheatley AK, Kent SJ. Aggregation by peptide conjugation rescues poor immunogenicity of the HA stem. Plos One 2020;15:e0241649

320. Khoury DS, Wheatley AK, Ramuta M, Reynaldi A, Cromer D, Subbarao K, O’Connor DH, Kent SJ, Davenport MP. Measuring immunity to SARS-CoV-2 infection: Antibodies, assays, and animals. Nature Reviews Immunology 2020;20:727-38

319. Nguyen THO, Koutsakos M, van de Sandt CE, Crawford JC, Loh L, Sant S, Grzelak L, Allen EK, Brahm T, Clemens EB, Auladell M, Hensen L, Wang Z, Nussing S, Jia X, Gunther P, Wheatley AK, Kent SJ, Aban M, Deng YM, Laurie KL, Hurt AC, Gras S, Rossjohn J, Crowe J, Xu J, Jackson DC, Brown LE, Gruta N, Chen W, Doherty PC, Turner SJ, Kotsimbos TC, Thomas PG,  Cheng AC, Kedzierska K. Immune cellular networks underlying recovery from influenza virus infection in acute hospitalized patients. Nature Communications 2021;12:2691

318. Sivaram AJ, Wardiana A, Alcantara S, Sonderegger SE, Fletcher NL, Houston ZH, Howard CB, Mahler SM, Alexander C, Kent SJ, Bell CA, Thurecht KJ. Controlling the biological fate of micellar nanoparticles: Balancing stealth and targeting. ACS Nano 2020;14:13739-13753

317. Tan HX, Juno JA, Lee WS, Barber-Axthelm IM, Kelly HG, Wragg KM, Esterbauer R, Amarasena T, Mordant FL, Subbarao K, Kent SJ*, Wheatley AK*. Prime-boost protein subunit vaccines against SARS-CoV-2 are highly immunogenic in mice and macaques. Nature Communications 2021;12:1403

316. Barber-Axthelm IM, Kelly HG, Esterbauer R, Wragg K, Gibbon A, Lee WS, Wheatley AK, Kent SJ, Tan HX, Juno JA. Coformulation with tattoo ink for immunological assessment of vaccine immunogenicity in the draining lymph node. J Immunol 2021

315. Habel J, Nguyen THO, van de Sandt CE, Juno JA, Chaurasia P, Wragg KM, Kousakos M, Hensen L, Jia X, Chua B, Zhang W, Tan HX, Flanagan KL, Doolan DL, Torresi J, Chen W, Wakim L, Cheng A, Doherty PC, Rossjohn J, Wheatley AK, Kent SJ, Rowntree L, Kedzierska K. Suboptimal SARS-CoV-2-specific CD8+ T-cell response associated with the prominent HLA-A*02:01 phenotype. PNAS 2020

314. Lee WS, Wheatley AK, Kent SJ*, DeKosky BJ*. Antibody-dependent Enhancement of SARS-CoV-2: Implications for Vaccines and Therapies. Nature Microbiology 2020; 14:15723-15737.

313. Koutsakos M, Sekiya T, Chua B, Nguyen O, Wheatley AK, Juno JA; Ohno M, Nomura N, Ohara Y, Nishimura T, Endo M, Suzuki S, Ishigaki H, Nakayama M, Nguyen C, Itoh Y, Shingai M, Ogasawara K, Kino Y, Kent SJ, Jackson DC, Brown L, Kida H, Kedzierska K. Immune profiling of influenza-specific B cell and T cell responses in macaques using flow cytometry-based assays. Immunol Cell Biol 2020

312. Barber-Axthelm I, Kent SJ, Juno JA. Understanding the Role of Mucosal-Associated Invariant T-cells in Nonhuman Primate Models of HIV Infection. Frontiers in Immunology 2020

311. Ahlensteil CL, Symonds G, Kent SJ, Kelleher AD. Block and Lock HIV Cure Strategies to Control the Latent Reservoir. Frontiers Cellular and Infection Microbiology 2020

310. Qu Y, Ju Y, Cortez-Jugo C, Lin X, Li S, Zhou J, Ma Y, Glab A, Kent SJ, Cavalieri F, Caruso F. Template-Mediated Assembly of DNA into Microcapsules for Immunological Modulation. Small 2020;16:e2002750

309. Juno J, Tan HX, Lee WS, Reynaldi A, Kelly HG, Wragg K, Esterbauer R, Kent HE, Batten CJ, Mordant FL, Gherardin NA, Pymm P, Dierich MH, Scott NE, Tham WH, Godfrey DI, Subbarao K, Davenport MP, Kent SJ*, Wheatley AK*. Humoral and circulating follicular helper T cell responses in recovered COVID-19 patients. Nature Medicine. 2020 26:1428-34

308. Selva KJ, van de Sandt CE, Lemke MM, Lee C, Shoffner SK, Chua BY, Davis SK, Nguyen THO, Rowntree LC, Hensen L, Koutsakos M, Wong CY, Subbarao K, Mordant F, Jackson DC, Flanagan KL, Crowe J, Tosif S, Neeland M, Sutton P, Licciardi P, Crawford N, Cheng AC, Doolan DL, Amanat F, Krammer F, Chappell K, Modhiran N, Watterson D, Young P, Lee WS, Wines B, P. Hogarth PM, Esterbauer R, Kelly HG, Tan HX, Juno JA, Wheatley AK, Kent SJ, Arnold KB, Kedzierska K, Chung AW. Distinct systems serology features in children, elderly and COVID-19 patients. Nature Communications 2021;12:2037

307. Vu MN, Kelly HG, Wheatley AK, Pilkington EH, Peng S, Davis TP, Kent SJ*, Truong NP*. Cellular interactions of liposomes and PISA nanoparticles during human blood flow in a microvascular network. Small 2020

306. Wong J, Tai CM, Hurt AC, Tan HX, Kent SJ*, Wheatley AK*. Sequencing B cell receptors from ferrets (Mustela putorius furo). Plos One 2020

305. Wragg K, Tan HX, Kristensen AB, Nguyen-Robertson CV, Kelleher AD, Parsons MS, Wheatley AK, Berzins SP, Pellicci DG, Kent SJ*, Juno JA*. CD26 and low CD94 expression identifies an IL-23 responsive V-gamma2+ T cell subset with a MAIT cell-like transcriptional profileCell Reports 2020

304. Tjandra KC, Forest CR, Wong CK, Alcantara S, Kelly HG, Ju Y, Stenzel MH, McCarroll JA, Kavallaris M, Caruso F, Kent SJ, Thordarson P. Modulating the selectivity and stealth properties of ellipsoidal polymersomes through a multivalent peptide ligand displayAdvanced Healthcare Materials 2020

303. Juno JA, Kent SJ. What can gamma delta T cells contribute to an HIV cure? Frontiers in Cellular Infection and Microbiology 2020

302. Kelly HG , Tan HX, Juno J, Esterbauer R, Ju Y, Jiang W, Wimmer VC, Duckworth BC, Groom JR, Caruso F, Kanekiyo M, Kent SJ*, Wheatley AK*. Self-assembling influenza nanoparticle vaccines drive extended germinal center activity and memory B cell maturationJCI Insight 2020;5:e136653.

301. Suphaphiphat K , Bernard-Stoecklin S, Gommet C, Delache B, Dereuddre-Bosquet N, Kent SJ, Wines BD, Hogarth PM, Le Grand R, Cavarelli M. Innate and adaptive anti-SIV responses in macaque semen: implications for infectivity and risk of transmissionFrontiers in Immunology 2020

300. Fu C, Demir B, Alcantara S, Kumar V, Han F, Kelly HG, Tan X, Yu Y, Xu W, Zhao J, Zhang C, Peng H, Boyer C, Woodruff TM, Kent SJ, Searles D, Whittaker AK. Low-fouling Fluoropolymers for Bioconjugation and In Vivo Tracking. Angewandte Chemie 2020

299. Vanderven HA, Barr I, Reynaldi A, Wheatley AK, Wines BD, Davenport MP, Hogarth PM, Kent SJ. Fc Functional Antibody Responses to Adjuvanted versus Unadjuvanted Seasonal Influenza Vaccination in Community-dwelling Older Adults. Vaccine 2020

298. Vanderven HA, Kent SJ. The protective potential of Fc-mediated antibody functions against influenza virus and other viral pathogens. Immunol and Cell Biol 2020

297. Nguyen B, Chung AW, Lopez S, Silvers J, Kent HE, Kent SJ, Downie L. Meibomian gland dropout is associated with immunodeficiency at HIV diagnosis: implications for dry eye disease. Ocular Surface 2020

296. Rigau M, Ostrouska S, Fulford TS, Johnson DN, Woods K, Ruan Z, McWilliam HE, Hudson C, Tutuka C, Wheatley AK, Kent SJ, Villadangos JA, Pal B, Kurts C, Simmonds J, Pelzing M, Hammet A, Verhagen AM, Vairo G, Maraskovsky E, Panousis C, Gherardin NA, Cebon J, Godfrey DI, Behren A, Uldrich AP. Butyrophilin 2A1 mediates phosphoantigen reactivity by gamma-delta T cells. Science 2020

295. McLean MR, Lu L, Kent SJ, Chung AW. An inflammatory story: antibodies in Mycobacterium tuberculosis co-morbidities. Frontiers Immunol 2019

294. Davis SK, Selva KJ, Kent SJ, Chung AW. Serum IgA Fc effector functions in infectious disease. Immunol and Cell Biol 2020

293. Billings H, Wines BD, Dyer WB, Center RJ, Trist HM, Kent SJ, Hogarth PM. Boosting of Markers of Fcγ Receptor Function in Anti-HIV Antibodies During Structured Treatment Interruption. AIDS Res Hum Retroviruses. 2019;35:842-852. doi: 10.1089/AID.2019.0047.

292. Faridi A, Yang W, Kelly HG, Wang C, Davis T, Chen P, Kent SJ, Ke PC. Differential roles of plasma protein corona on immune cell association and cytokine secretion of oligomeric and fibrillar beta-amyloid. Biomacromolecules 2019

291. Lopez E, Scott NE, Wines BD, Hogarth PM, Wheatley AK, Kent SJ, Chung AW. Low pH exposure during Immunoglobulin G purification methods results in aggregates that avidly bind Fcγ Receptors: Implications for measuring Fc dependent antibody functions. Frontiers in Immunology 2019

290. Selva KJ, Bavinton BR, Grulich AE, Pazgier M, Kelleher AD, Kent SJ, Parsons MS. Impact of HIV-1 viremia or sexually transmitted infection on semen-derived anti-HIV-1 antibodies and the immunosuppressive capacity of seminal plasma. Eur J Immunol. 2019 doi: 10.1002/eji.201848055

289. Wong J, Layton D, Wheatley AK, Kent SJ. Improving immunological insights into the ferret model of human viral infectious disease. Influenza and Other Respiratory Viruses. 2019

288. Kesarwani V, Kelly HG, Shankar M, Robinson KJ, Kent SJ, Traven A, Corrie SR. Characterisation of key bio-nano interactions between organosilica nanoparticles and Candida albicans. ACS Applied Materials & Interfaces 2019; 11: 34676−34687

287. Weiss ACG, Kelly HG, Faria M, Besford QA, Wheatley AK, Ang C-S, Crampin EJ, Caruso F, Kent SJ. Link between Low-Fouling and Stealth: A Whole Blood Biomolecular Corona and Cellular Association Analysis on Nanoengineered Particles. ACS Nano 2019 DOI: 10.1021/acsnano.9b00552

286. Selva KJ, Juno JA, Worley MJ, Chung AW, Tachedjian G, Kent SJ, Parsons MS. Effect of seminal plasma on functions of monocytes and granulocytes. AIDS Res Human Retroviruses 2019 DOI: 10.1089/AID.2018.0219

285. Kent SJ, Davenport MP. Moving the HIV vaccine field forward: concepts of protective immunity. Lancet HIV 2019 DOI: 10.1016/S2352-3018(19)30134-1

284. Bangaru S, Zhang H, Gilchuk IM, Voss TG, Irving RP, Gilchuk P, Matta P, Zhu X, Lang S, Nieusma T, Richt JA, Randy A. Albrecht RA, Hillary A. Vanderven HA, Bombardi R, Kent SJ, Ward AB, Wilson IA, Crowe JE. A Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain Trimer Interface. Cell 2019:177;1136–1152 DOI: 10.1016/j.cell.2019.04.011. See accompanying editorial here.

283. Cui J, Ju Y, Houston ZH, Glass JJ, Fletcher NL, Alcantara S, Dai Q, Howard CB, Mahler SM, Wheatley AK, De Rose R, Brannon PT, Paterson BM, Donnelly PS, Thurecht KJ, Caruso F, Kent SJ. Modulating Targeting of Poly(ethylene glycol) Particles to Tumor Cells Using Bispecific Antibodies.Adv Healthcare Materials 2019 DOI: 10.1002/adhm.201801607

282. Lee WS, Prevost J, Richard J, van der Sluis RM, Lewin SR, Pazgier M, Finzi A, Parsons MS, Kent SJ. CD4- and Time-Dependent Susceptibility of HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity. J Virol 2019 doi:10.1128/JVI.01901-18

281. Lewis GK, Ackerman ME, Scarlatti G, Moog C, Robert-Guroff M, Kent SJ, Overbaugh J, Reeves K, Ferrari G, Thyagarajan B. Knowns and Unknowns of Assaying Antibody-dependent Cell-mediated Cytotoxicity Against HIV-1. Frontiers in Immunology 2019

280. Khanna M,Jackson RJ, Alcantara S, Thakshila H Amarasena TH, Li Z, Anthony D Kelleher AD,Kent SJ, Ranasinghe C. Complete protection following high dose intrarectal SIVmac239 challenge following intranasal pox viral-vector based vaccination, correlates with combined mucosal/systemic cytotoxic CD4+ T cell immunity. Scientific Reports 2019

279. Juno JA, Wragg KM, Kristensen AB, Lee WS, Selva K, van der Sluis R, Kelleher AD, Bavinton B, Grulich A, Lewin SR, Kent SJ, Parsons MS. Modulation of the CCR5 receptor/ligand axis by seminal plasma and the utility of in vitro versus in vivo modelsJ Virol 2019 doi:10.1128/JVI.00242-19

278. Tan HX, Esterbauer R, Vanderven H, Juno JA, Kent SJ, Wheatley AK. Inducible bronchus-associated lymphoid tissues (iBALT) serve as sites of B cell selection and maturation following influenza infection in mice
Frontiers in Immunology 2019 doi: 10.3389/fimmu.2019.00611

277 Jiang W, Wragg KM, Tan HX, Kelly HG, Wheatley AK, Kent SJ, Juno JA. Identification of murine antigen-specific T follicular helper cells using an activation-induced marker assayJ Immunol Methods 2019;267:48-57

276. Juno JA, Wragg KM, Amarasena T, Meehan BS, Mak JYW, Liu L, Fairlie D, McCluskey J, Eckle SBG, Kent SJ. MAIT cells upregulate a4b7 in response to acute SIV/SHIV infection but are resistant to peripheral depletion in pigtail macaquesJournal of Immunology. 2019 doi/10.4049/jimmunol.1801405. Highlighted in "in this issue".

275. Damelang T, Rogerson SJ, Kent SJ, Chung AW. The Role of IgG3 in Infectious DiseasesTrends in Immunology 2019 See front cover here.

274. Kelly HG, Kent SJ, Wheatley AK. Immunological basis for enhanced immunity of nanoparticle vaccinesExpert Review of Vaccines. 2019

273. Liu Y, Tan HX, Koutsakos M, Jegaskanda S, Esterbauer R, Tilmanis A, Aban M, Kedzierska K, Hurt AC, Kent SJ, Wheatley AK. Cross-lineage protection by human antibodies binding the influenza B hemagglutinin. Nature Communications 2018

272. Tan HX, Jegaskanda S, Juno JA, Esterbauer R, Wong J, Kelly HG, Liu Y, Tilmanis D, Hurt AC, Yewdell JW, Kent SJ, Wheatley AK. Subdominance and poor intrinsic immunogenicity limit humoral immunity targeting the influenza HA stem. Journal of Clinical Investigation 2018

271. Jegaskanda S, Vanderven HA, Tan HX, Alcantara S, Wragg K, Parsons MS, Chung AW, Juno JA, Kent SJ. Influenza infection enhances antibody-mediated NK cell functions via Type I interferon dependent pathways.J Virol 2018;5:e02090-18

270. Anand SP, Prévost J, Baril S, Richard J, Medjahed H, Chapleau J-P, Tolbert W, Kirk S, Smith A, Wines B, Kent SJ, Hogarth PM, Parsons MS, Pazgier M, Finzi A. Two families of Env antibodies efficiently engage Fc-gamma receptors and eliminate HIV-1-infected cells. J Virol 2018 DOI: 10.1128/JVI.01823-18

269. Kent SJ, Flexner C. Ageing and patients with chronic HIV infection. AIDS Research and Therapy. 2018;15:22 DOI: 10.1186/s12981-018-0211-1

268. Juno JA, Phetsouphanh C, Klenerman P, Kent SJ. Perturbation of MAIT and iNKT cells in HIV infection. Current Opinion in HIV/AIDS. 2018 2019;14:77-84

267. Parsons MS, Kristensen AB, Lee WS, Amarasena T, Khoury G, Wheatley AK, Reynaldi A, Wines BD, Hogarth PM, Kent SJ. Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques. Journal of Clinical Investigation 2018 See editorial by Forthal and FInzi here.

266. Davenport MD, Khoury D, Cromer D, Lewin SR, Kelleher AD, Kent SJ. Functional cure of HIV: The scale of the challenge. Nature Reviews Immunology 2018

265. Chen L, Glass JJ De Rose R, Sperling C, Kent SJ, Houston Z, Fletcher N, Rolfe B, Thurecht K. The influence of charge on hemocompatibility and immunoreactivity of polymeric nanoparticles. ACS Applied Bio Materials 2018;1:756-767.

264. Kent SJ, Hough S, Kelleher AD, Law MG, Hutchinson J, Catalfamo M, van Bockel D, Lane C, Baker JV, Emery S for the ADVICE study group. Randomised double-blind placebo-controlled trial of vorapaxar for HIV associated inflammation and coagulopathy – the ADVICE study. Lancet HIV; 2018 See also accompanying editorial here.

263. Parsons MS, Chung AW, Kent SJ. Importance of Fc-mediated functions of anti-HIV-1 broadly neutralizing antibodies. Retrovirology; 2018;15:58.

262. Lopez E, Shattock RJ, Kent SJ, Chung AW. The multi-faceted nature of Immunoglobulin A and its complex role in HIV. AIDS Research and Human Retroviruses; 2018;34:727-738.

261. Faria M, Björnmalm M, Thurecht K, Kent SJ, Parton R, Kavallaris M, Johnston APR, Gooding J, Corrie S, Boyd BJ, Thordarson P, Whittaker A, Stevens M, Prestidge C, Porter C, Parak W, Davis T, Crampin E, Caruso F. Minimum Information Reporting in Bio–Nano Experimental Literature. Nature Nanotechnology; 2018;13:777-785.

260. Anania JC, Trist HM, Palmer CS, Tan PS, Kouskousis BP, Chenoweth AM, Kent SJ, Hoi H, Mackay GA, Koelmeyer R, Slade C, Bryant VL, Hodgkin PD, Aui PM, van Zelm MC, Wines BD, Hogarth PM. The human Fc-gamma-RIIa3 associated with anaphylaxis in immunoglobulin replacement therapy exhibits distinct characteristics from the canonical Fc-gamma-RIIa1. Frontiers in Immunology 2018:9:1809

259. Cheeseman HM, Day S, McFarlane LR, Fleck S, Miller A, Cole T, Sousa-Santos N, Cope AV, Cizmeci D, Tolazzi M, Hwekwete E, Hannaman D, Kratochvil S, McKay PF, Chung AW, Kent SJ, Cook A, Scarlatti G, Abraham S, Combadiere B, McCormack S, Lewis DJ, Shattock RJ. Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to an HIV-1 Clade C Envelope VaccineHuman Gene Therapy. 2018:29:1011-1028.

258. Vanderven HA, Wragg K, Ana-Sosa-Batiz F, Kristensen AB, Jegaskanda S, Wheatley AK, Wentworth D, Wines BD, Hogarth PM, Rockman S, INSIGHT FLU005 Pilot Study Writing Group, Kent SJ. Anti-influenza hyperimmune immunoglobulin enhances Fc-functional antibody immunity during human influenza infection. Journal of Infectious Diseases; 2018

257. Parsons MS, Le Grand R, Kent SJ. Utility of broadly neutralizing antibodies to prevent cell-associated HIV-1 infection. Viruses 2018;10:333.

256. Bangaru S, Zhang H, Gilchuk IM, Voss TG, Irving RP, Gilchuk P, Matta P, Zhu X, Lang S, Nieusma T, Richt JA, Albrecht RA, Vanderven HA, Bombardi R, Kent SJ, Ward AB, Wilson IA, Crowe JE. A human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA exploits multiple antiviral strategies. Nature Communications 2018;9:2669.

255. Juno JA, Waruk JLM, Wragg KM, Mesa C, Lopez C, Joe Bueti J, Kent SJ, Ball TB, Kiazyk SA. MAIT cells are depleted and exhibit altered chemokine receptor expression and elevated GM-CSF production during end stage renal disease. Frontiers in Immunology 2018;9:1076.

254. Carroll TD, Jegaskanda S, Matzinger SR, Fritts L, McChesney MB, Kent SJ, Fairman J, Miller CJ. A lipid/DNA adjuvant-inactivated influenza virus vaccine protects rhesus macaques from uncontrolled virus replication after heterosubtypic influenza A virus challenge. Journal of Infectious Diseases 2018;

253. Worley MJ, Fei K, Lopez-Denman AJ, Kelleher AD, Kent SJ, Chung AW. Neutrophils mediate HIV-specific antibody-dependent phagocytosis and ADCC. J Immunol Methods 2018;457:41-52.

252. Wang M, Gustafsson O, Siddiqui G, Javed I, Kelly H, Blin T, Yin H, Kent SJ, Creek D, Kempe K, Ke PC, Davis T. Human plasma proteome association and cytotoxicity of nano-graphene oxide grafted with stealth polyethylene glycol and poly(2-ethyl-2-oxazoline). Nanoscale 2018;

251. Rasmussen TA, McMahon JH, Chang JJ, Audsley J, Rhodes A, Tennakoon S, Dantanarayana A, Spelman T, Schmidt T, Kent SJ, Morcilla V, Palmer S, Elliott JH, Lewin SR. The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV infected individuals: A randomised, placebo-controlled, double blind clinical trial. The Lancet HIV 2018; Published online April 8, 2018;

250. Kristensen AB, Kent SJ, Parsons MS. Contribution of NK cell education to both direct and anti-HIV-1 antibody-dependent NK cell functions. Journal of Virology 2018;92:e02146-17

249. Ramarathinam SH, Gras S, Alcantara S, Yeung A, Mifsud NA, Sonza S, Illing PT, Center RJ, Thomas S, Kent SJ, Ternette N, Purcell DFJ, Rossjohn J, Purcell AW. Identification of native and post-translationally modified HLA-B*57:01-restricted HIV envelope derived epitopes using immunoproteomics. Proteomics 2018;18:1700253

248. Catton M, Gray G, Griffin D, Hasegawa H, Kent SJ, Mackenzie J, McSweegan E, Mercer N, Wang L. 2017 International Meeting of the Global Virus Network. Antiviral Research 2018; 153: 60-69.

247. Koutsakos M, Wheatley AK, Loh L, Clemens EB, Sant S, Nüssing S, Fox. A., Chung AW, Laurie KL, Hurt AC, Rockman S, Lappas M, Loudovaris T, Mannering SI, Westall GP, Elliot M, Tangye SG, Wakim LM, Kent SJ, Nguyen THO and Kedzierska K.  Circulating Tfh cells, serological memory and tissue compartmentalization shape human influenza-specific B cell immunity. Science Translational Medicine 2018; 10:eaan8405.

246. Parsons MS, Cromer D, Davenport MP, Kent SJ. HIV reactivation after partial protection by neutralizing antibodies. Trends in Immunology 2018;39:359-366

245. Kratochvil S, MacKay PF, Chung AW, Kent SJ, Gilmore J, Shattock RJ. IgG1 allotype influences antibody subclass abundance in response to HIV gp140 vaccination. Frontiers in Immunology 2017; 8: 1883.

244. Lee WS, Kent SJ. Anti-HIV-1 ADCC: is there more to antibodies than neutralization? Current Opinion in HIV/AIDS 2018; 13: 160-166.

243. Kent SJ, Chung AW. A Role for Fc-Mediated Humoral Immunity in Reducing HIV Transmission Rates between HIV Serodiscordant Heterosexual Couples. EBiomedicine 2017; 26: 2-3.

242. Vanderven HA, Jegaskanda S, Wines BD, Hogarth PM, Carmuglia S, Rockman S, Chung AW, Kent SJ. Antibody dependent cellular cytotoxicity immune responses to seasonal influenza vaccination in the elderly. Journal of Infectious Diseases 2017; 217: 12-23.

241. Cromer D, Pinkevych M, Rasmussen T, Lewin S, Kent SJ, Davenport MP.  Modelling of anti-latency treatment in HIV; What is the optimal duration of anti-retroviral-free HIV remission? J Virol 2017: 91(24): e01395-17.

240. Ana-Sosa-Batiz F, Johnston APR, Hogarth PM,  Wines BD, Barr I, Wheatley AK, Kent SJ. Antibody-dependent phagocytosis (ADP) responses following trivalent inactivated influenza vaccination of younger and older adults. Vaccine 2017; 35: 6451–6458.

239. Song D, Cui J, Sun H, Nguyen TH, Alcantara S, De Rose R, Kent SJ, Porter CJH, Caruso F. Templated Polymer Replica Nanoparticles to Facilitate Assessment of Material-Dependent Pharmacokinetics and Biodistribution.  ACS Applied Materials and Interfaces. 2017; 9: 33683-33694..

238. Tan HX, Wheatley AK, Glass JJ, Masopust D, De Rose R, Kent SJ. Induction of Vaginal Resident HIV-specific CD8 T-cells with Mucosal Prime-Boost Immunisation. Mucosal Immunology 2017; doi:10.1038/mi.2017.89.

237. Lloyd SB, Niven KP, Kiefel BR, Montefiori DC, Reynaldi A, Davenport MP, Kent SJ, Winnall WR. Exploration of broadly neutralizing antibody fragments produced in bacteria for the control of HIV. Human Vaccines and Immunotherapeutics 2017; 13(11): 2726-2737.

236. Madhavi V, Wines BD, Amin J, Emery S, ENCORE1 Study Group, Lopez E, Kelleher A, Sydney LTNP Study Group, Center RG, Hogarth PM, Chung AW, Kent SJ, Stratov I. HIV-1 Env- and Vpu-specific antibody-dependent cellular cytotoxicity responses associated with elite control of HIV. J Virology 2017: 91(18): 1-16.

235. Lee WS, Kristensen AB, Rasmussen TA, Tolstrup M, Østergaard L, Søgaard OS, Wines BD, Hogarth PM, Reynaldi A, Davenport M, Emery S, Amin J, Cooper DA, Kan V, Fox J, Grüll H, Parsons MS, Kent SJ. Anti-HIV-1 ADCC antibodies following latency reversal and treatment interruption. Journal of Virology 2017; 91: e00603.

234. Vanderven HA, Liu L, Ana-Sosa-Batiz F, Nguyen TH, Wan Y, Wines B, Hogarth PM, Tilmanis D, Reynaldi A, Parsons MS, Hurt AC, Davenport MP, Kotsimbos T, Cheng AC, Kedzierska K, Zhang X, Xu J, Kent SJ. Fc functional antibodies during severe human H7N9 and seasonal influenza. JCI Insight 2017; 2: e92750.

233. Mclean MR, Madhavi V, Wines BD, Hogarth PM, Chung A, Kent SJ. Dimeric Fcγ receptor ELISA to study HIV-specific antibodies: a new look into breadth of Fcγ receptor antibodies induced by the RV144 vaccine trial. The Journal of Immunology 2017; 199: 816-26.

232. Glass JJ, Chen L, Alcantara S, Crampin EJ, Thurecht KJ, De Rose R, Kent SJCharge has a marked influence on hyperbranched polymer nanoparticle association in whole human blood. ACS Macro Letters 2017; 6: 586-592.

231. Parsons MS, Lloyd SB, Lee WS, Kristensen AB, Amarasena T, Center RJ, Keele BF, Lifson JD, LaBranche CC, Montefiori D, Wines BD, Hogarth PM, Swiderek KM, Venturi V, Davenport MP, Kent SJ. Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection. Science Translational Medicine 2017; 09 Aug; 9(402): eaaf1483 DOI: 10.1126/scitranslmed.aaf1483. See Abstract. See Full Text.  For Reprint.

230. Kratochvil S, McKay PF, Kopycinski JT, Bishop C, Hayes PJ, Muir L, Pinder CL, Cizmeci D, King D, Aldon Y, Wines BD, Hogarth M, Chung AW, Kent SJ, Held K, Geldmacher C, Dally L, Santos NS, Cole T, Gilmour J, Fidler S, Shattock RJ. A Phase I HIV vaccine trial for cross-profiling the kinetics of serum and mucosal antibody responses to CN54gp140 modulated by two homologous prime-boost vaccine regimens. Frontiers in Immunology 2017; 8: 595.

229. Jegaskanda S, Vanderven HA, Wheatley AK, Kent SJ. Fc or not Fc; that is the question: Antibody Fc-receptor interactions are key to universal influenza vaccine design. Human Vaccines and Immunotherapeutics 2017; ePub: 1-9.

228. Rasmussen TA, McMahon J, Chang JJ, Symons J, Roche M, Dantanarayana A, Okoye A, Hiener B, Palmer S,  Lee WS, Kent SJ, Van Der Weyden C, Prince HM, Cameron PU, Lewin SR. Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndrome. AIDS 2017; 31: 1839-45.

227. Zaunders J, Xu Y, Kent SJ, Koelsch KK, Kelleher AD. Divergent expression of CXCR5 and CCR5 on CD4+ T cells and the paradoxical accumulation of T follicular helper cells during HIV infection. Frontiers in Immunology 2017; 8: Article 495.

226. Rockman S, Lowther S, Camuglia S, Vandenberg K, Taylor S, Fabri L, Miescher S, Pearse M, Middleton D, Kent SJ, Maher D. Intravenous immunoglobulin protects against severe pandemic influenza infection. EBioMedicine 2017; 19: 119-27.

225. Glass JJ, Li Y, De Rose R, Johnston A, Czuba E, Khor SY, Quinn J, Whittaker M, Davis T, Kent SJThiol-Reactive Star Polymers display enhanced association with distinct human blood components. ACS Applied Materials & Interfaces 2017; 9: 12182-94.

224. Wines BD, Billings H, Mclean MR, Kent SJ, Hogarth PM. HIV-specific ADCC - new technologies to study ADCC and importance for the HIV vaccine field. Current HIV Research 2017; 15: 202-15.

223. Kent SJ. HIV Vaccine Approaches. In: eLS. John Wiley & Sons, Ltd: Chichester. DOI: 10.1002/9780470015902.a0021550.pub3.

222. Madhavi V, Kulkarni A, Shete A, Lee WS, Mclean MR, Kristensen AB, Ghate M, Wines BD, Hogarth PM, Parsons MS, Kelleher AD, Cooper DA, Amin J, Emery S, Thakar M, Kent SJEffect of combination antiretroviral therapy on HIV-1-specific antibody-dependent cellular cytotoxicity responses in subtype B- and subtype C-infected cohorts. J AIDS 2017; 75: 345-353.

221. Kent SJ, Kelleher AD. Expanding role for Type I Interferons in restricting HIV growth. Immunology and Cell Biology 2017; 95: 417-18.

220. Petravic J, Rasmussen TA, Lewin SR, Kent SJ, Davenport MP. Relationship between measures of HIV reactivation and the decline of latent reservoir under latency-reversing agents. J Virol 2017; 91: e02092-16.

219. Xu Y, Phetsouphanh C, Suzuki K, Aggarwal A, Graff-Dubois S, Roche M, Bailey M, Alcantara S, Flanagan S, Cash K, Siva R, Koelsch KK, Autran B, Harvey R, Gorry PR, Moris A, Cooper DA, Turville S, Kent SJ, Kelleher AD, Zaunders J. HIV-1 and SIV predominantly use CCR5 expressed on a precursor population to establish infection in T follicular helper cells. Frontiers in Immunology 2017; 8: Article 376.

218. Juno JA, van Bockel D, Kent SJ, Kelleher AD, Zaunders JJ, Munier CM. Cytotoxic CD4 T cells - friend or foe during viral infection? Frontiers in Immunology 2017; 8: Article 19.

217. Gause KT, Wheatley AK, Cui J, Yan Y, Kent SJ, Caruso F. Immunological principles guiding the rational design of particles for vaccine delivery. ACS Nano 2017; 11: 54-68.

216. Kulkarni A, Kurle S, Shete A, Ghate M, Godbole S, Madhavi V, Kent SJ, Paranjape R, Thakar M. Indian long-term non-progressors show broad ADCC responses with preferential recognition of V3 region of Envelope and a region of Tat protein. Frontiers in Immunology 2017; 8: 5.

215. Vanderven HA, Jegaskanda S, Wheatley AK, Kent SJ. Antibody dependent cellular cytotoxicity and influenza virus. Current Opinion in Virology 2017; 22: 89-96.

214. Selva KJ, Kent SJ, Parsons MS. Modulation of innate and adaptive cellular immunity relevant to HIV-1 vaccine design by seminal plasma. AIDS 2017; 31: 333-42.

213. Pinkevych M, Kent SJ, Tolstrup M, Lewin SR, Cooper DA, Søgaard OS, Rasmussen TA, Kelleher AD, Cromer D, Davenport MP. Modeling of experimental data supports HIV reactivation from latency after treatment interruption on average once every 5-8 days. Plos Pathogens 2016; 12: e1005740

212. Parsons MS, Richard J, Lee WS, Vanderven H, Grant MD, Finzi A, Kent SJ. NKG2D acts as a co-receptor for natural killer cell-mediated anti-HIV-1 antibody-dependent cellular cytotoxicity. AIDS Research and Human Retroviruses 2016; 32: 1089-96.

211. Munier CML, van Bockel D, Bailey M, Ip S, Xu Y, Alcantara S, Liu SM, Denyer G, Kaplan W, PHIIDO Study group, Suzuki K, Croft N, Purcell A, Tscharke D, Cooper DA, Kent SJ, Zaunders JJ, Kelleher AD. The primary immune response to Vaccinia virus vaccination includes cells with a distinct cytotoxic effector CD4 T-cell phenotype. Vaccine 2016; 34: 5251-61.

210. Mann SK, Dufour A, Glass JJ, De Rose R, Kent SJ, Such GK, Johnston APR. Tuning the properties of pH responsive nanoparticles to control cellular interactions in vitro and ex vivo. Polymer Chemistry 2016; 7: 6015-24.

209. Wheatley AK, Kent SJTwist in the Tail: Escape from HIV neutralising antibodies at a single site confers broad susceptibility to others. EBioMedicine 2016; 12: 14-15.

208. Wines BD, Vanderven HA, Esparon SE, Kristensen AB, Kent SJ, Hogarth PM. Dimeric FcγR ectodomains as probes of the Fc-receptor function of anti-Influenza Virus IgG. The Journal of Immunology 2016; 197: 1507-16.

207. Wheatley AK, Kristensen AB, Lay WN, Kent SJ. HIV-dependent depletion of influenza-specific memory B cells may impacts B cell responsiveness to seasonal influenza immunisation. Scientific Reports 2016; 6: 26478.

206. Vanderven HA, Ana-Sosa-Batiz F,  Jegaskanda S, Rockman S, Laurie K, Barr I, Chen W, Wines B, Hogarth PM, Lambe T, Gilbert SC, Parsons MS, Kent SJ. What lies beneath: Antibody dependent natural killer cell activation by antibodies to internal influenza virus proteins. Ebiomedicine 2016; 8: 277-90.

205. Ana-Sosa-Batiz F, Vanderven H, Jegaskanda S, Johnston APR, Rockman S, Laurie K, Barr I, Reading P, Lichtfuss M, Kent SJ. Influenza-specific antibody-dependent phagocytosis. Plos One 2016; 11: e0154461 .

204. Kristensen AB, Lay WN, Ana-Sosa-Batiz F, Vanderven HA, Madhavi V, Laurie KL, Carolan L, Wines BD, Hogarth M, Wheatley AK, Kent SJ. Antibody responses with Fc-mediated functions after vaccination of HIV-infected subjects with trivalent influenza vaccine. Journal of Virology 2016; 90: 5724-34.

203. Kent SJ, Kim JH. HIV vaccines moving forward. Current Opinion HIV AIDS; 11: 545.

202. Gooneratne SL, Center RJ, Kent SJ, Parsons MS. Functional advantage of educated KIR2DL1(+) natural killer cells for anti-HIV-1 antibody-dependent activation. Clinical & Experimental Immunology 2016; 184: 101-9.

201. Glass JJ, Yuen D, Rae J, Johnston APR, Parton RG, Kent SJ, De Rose R. Human immune cell targeting of protein nanoparticles – caveospheres. Nanoscale 2016; 8: 8255-65.

200. Glass JJ, De Rose R, Kent SJ. Enhancing dendritic cell activation and HIV vaccine effectiveness through nanoparticle vaccination. Expert Review of Vaccines 2016; 15: 719-29.

199. Beck SE, Queen SE, Viscidi R, Johnson D, Kent SJ, Adams RJ, Tarwater PM, Mankowski JL. Central nervous system-specific consequences of simian immunodeficiency virus Gag escape from major histocompatibility complex class I-mediated control. J Neurovirol 2016; 22: 498-507.

198. Lloyd SB, Lichtfuss M, Amarasena TH, Alcantara S, De Rose R, Tachedjian G, Alinejad-Rokny H, Venturi V, Davenport MP, Winnall WR, Kent SJ. High fidelity simian immunodeficiency virus reverse transcriptase mutants have impaired replication in vitro and in vivo. Virology 2016; 492: 1-10.

197. Tan HX, Gilbertson BP, Jegaskanda S, Alcantara S, Amarasena T, Stambas J, McAuley JL, Kent SJ, De Rose R. Recombinant Influenza Virus Expressing HIV-1 p24 Capsid Protein Induces Mucosal HIV-specific CD8 T-cell Responses. Vaccine 2016; 34: 1172-9.

196. Lee WS, Richard J, Lichtfuss M, Smith AB, Park J, Courter JR, Melillo BN, Sodroski JG, Kaufmann DE, Finzi A, Parsons MS, Kent SJ. Antibody dependent cellular cytotoxicity against reactivated HIV-1-infected cells. J Virol 2015; 90: 2021-30.

195. Parsons MS, Kent SJ. Paradox of protection: Preferential recognition of CD4-induced epitopes by anti-HIV-1 ADCC antibodies (Commentary). Ebiomedicine 2015; 2: 1298-9.

194. Kent SJ. Eradication and cure of HIV (Chapter 105). In Infectious Diseases, 2017 (4th edition, Editors Cohen, Powderly and Opal; Elsevier). pp 931-35.

193. Kent SJ*. That last knoll. Wild 2015; 150: 32-36. (*This is an article on bushwalking not a scientific article! Enjoy!).

192. Wheatley AK, Kent SJ. Prospects for antibody-based universal influenza vaccines in the context of widespread pre-existing immunity. Expert Review of Vaccines 2015; 14: 1227-1239.

191. Parsons MS, Madhavi V, Ana-Sosa-Batiz F, Center RJ, Wilson KM, Bunupuradah T, Ruxrungtham K, Kent SJ. Seminal plasma anti-HIV antibodies trigger antibody-dependent cellular cytotoxicity: Implications for HIV transmission. J AIDS 2016; 71: 17-23.

190. Tan HX, Kent SJ, De Rose R. Contemporary HIV vaccines: tissue resident T-cells and strategies to prevent mucosal infection. Current Topics in Medicinal Chemistry 2015; 16: 1107-17.

189. Pinkevych M, Cromer D, Tolstrup M, Grimm AJ, Cooper DA, Lewin SR, Søgaard OS, Rasmussen TA, Kent SJ, Kelleher AD, Davenport MP. HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission. Plos Pathogens 2015; 11: e1005000.

188. Lee WS, Parsons MS, Kent SJ, Lichtfuss M. Can HIV-1-specific ADCC assist the clearance of reactivated latently infected cells? Frontiers in Immunololgy 2015; 6: Article 265.

187. Martyushev AP, Petravic J, Grimm AJ, Alinejad-Rokny H, Gooneratne SL, Reece JC, Cromer D, Kent SJ, Davenport MP. Epitope-Specific CD8+ T Cell Kinetics Rather than Viral Variability Determine the Timing of Immune Escape in Simian Immunodeficiency Virus Infection. J Immunol 2015; 194: 4112-21.

186. Kent SJ. Trying to cure HIV with immunotherapy: not so simple (commentary). The Lancet HIV 2015; 2: e72-3.

185. Insight Start Study Group (Kent SJ Investigator). Initiation of Antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015; 373: 795-807.

184. Tang C-C, Isitman G, Bruneau J, Tremblay C, Bernard NF, Kent SJ, Parsons MS. Phenotypical and functional profiles of natural killer cells exhibiting matrix metalloproteinase-mediated CD16 cleavage after anti-HIV antibody-dependent activation. Clinical and Experimental Immunology 2015; 181: 275-85.

183. Cui J, De Rose R, Alt K, Alcantar S, Paterson B, Liang K, Hu M, Richardso, JJ, Yan Y, Jeffery C, Price R, Peter K, Hagemeyer C, Donnelly P, Kent SJ, Caruso F. Engineering Poly(ethylene glycol) Particles for Improved Biodistribution. ACS Nano 2015; 9: 1571-80.

182. Winnall WR, Lloyd SB, De Rose R, Alcantara S, Amarasena TH, Hedger MP, Girling JE, Kent SJ. Simian immunodeficiency virus infection and immune responses in the pig-tailed macaque testis. J Leuk Biol 2015; 97: 599-609.

181. Li J, Ahmet F, Sullivan LC, Brooks AG, Kent SJ, De Rose R, Salazar AM, Reis e Sousa C, Shortman K, Lahoud MH, Heath WR, Caminschi I. Antibodies targeting Clec9A promote strong humoral immunity without adjuvant in mice and non-human primates. Eur J Immunol 2015; 45: 854-64.

180. Kramski M, Stratov I, Kent SJ. The role of HIV-specific ADCC in HIV prevention and the influence of the HIV-1 Vpu protein. AIDS 2015; 29: 137-44.

179. Gooneratne S, Richard J, Lee WS, Finzi A, Kent SJ, Parsons MS. Slaying the Trojan horse: Natural killer cells exhibit robust anti-HIV-1 antibody-dependent activation and cytolysis against allogeneic T-cells. J Virol 2015; 89: 97-109.

178. Gooneratne S, Alinejad-Rokny H, Ebrahimi D, Bohn PS, Wiseman RW, O'Connor DH, Davenport MP, Kent SJ. Linking pig-tailed macaque major histocompatibility complex class I haplotypes and cytotoxic T lymphocyte escape mutations in SIV infection. J Virol 2014; 88: 14310-25.

177. Petravic J, Martyushev A, Reece JC, Kent SJ, Davenport MP. Modeling the timing of anti-latency drug administration during HIV treatment. J Virol 2014; 88: 14050-6.

176. Fernandez CS, Amarasena T, Kelleher AD, Rossjohn J, McCluskey J, Godfrey DI, Kent SJ. MAIT cells are depleted early but retain functional cytokine expression in HIV infection. Immunology and Cell Biology 2014; doi: 10.1038/icb.2014.91.

175. Parsons MS, Loh L, Gooneratne S, Center RJ, Kent SJ. Role of education and differentiation in determining the potential of NK cells to respond to antibody-dependent stimulation. AIDS. 2014; 28: 2781-8.

174. Kent SJ, Davenport MP. Tentative steps to eradicate latent HIV (commentary). The Lancet HIV. 2014; 1: e2-3.

173. Madhavi V, Ana-Sosa-Batiz F, Jegaskanda S, Center RJ, Winnall WR, Parsons MS, Ananworanich J, Cooper DA, Kelleher AD, Hsu D, Pett S, Stratov I, Kramski M, Kent SJ. Antibody-dependent effector functions against HIV decline in subjects on antiretroviral therapy. Journal of Infectious Diseases. 2015; 211: 529-38.

172. Florek N, Weinfurter J, Jegaskanda S, Brewoo J, Powell T, Young G, Das S, Hatta M, Broman K, Hungnes O, Dudman S, Kawaoka Y, Kent SJ, Stinchcomb D, Osorio J, Friedrich T. Modified vaccinia Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques. J Virol 2014; 88: 13418-28

171. Stratov I, Kent SJ. Antiretroviral therapy initiation in an Australian cohort - implications for increased use of antiretroviral therapy. European Journal of Clinical Microbiology and Infectious Diseases. 2015; 34: 253-259.

170. Jegaskanda S, Vandenberg K, Laurie KL, Loh L, Kramski M, Winnall WR, Kedzierska K, Rockman S, Kent SJ. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity in intravenous immunoglobulin as a potential therapeutic against emerging influenza viruses. Journal of Infectious Diseases 2014: 210: 1811-1822.

169. Jegaskanda S, Ahn SH, Skinner N, Thompson A, Ngyuen T, Holmes J, De Rose R, Navis N, Winnall WR, Kramski M, Bernardi G, Bayliss J, Colledge D, Sozzi V, Visvanathan K, Locarnini S, Kent SJ, and Revill P. Down-regulation of IL-18 mediated cell signalling and IFN-γ expression by the hepatitis B virus e antigen. J Virol 2014; 88: 10412-30.

168. De Rose R, Kent SJ, Ranasinghe C. Prime-boost vaccination: Impact on the HIV vaccine field. (Book Chapter). In Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies. (eds Singh and Salnikov) Elsevier 2015, pp 289-313.

167. Ana-Sosa-Batiz F, Johnston APR, Liu H, Center RJ, Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungal J, Kim JH, Michael NL, Kelleher AD, Stratov I, Kent SJ, Kramski M. HIV-specific antibody-dependent phagocytosis (ADP) matures during HIV infection. Immunology and Cell Biology 2014; 92: 679–687.

166. Madhavi V, Wren LH, Center RJ, Gonelli C, Winnall WR, Parsons MS, Kent SJ, Stratov I. Breadth of HIV-specific ADCC - Relevance to global HIV vaccine design. AIDS 2014; 28: 1859-70.

165. Winnall WR, Beasley MD, Center RJ, Parsons MS, Kiefel BR, Kent SJ. The maturation of antibody technology for the HIV epidemic. Immunology and Cell Biology 2014; 92: 570-77.

164. Jegaskanda S, Reading PC, Kent SJ. Influenza-specific ADCC – towards universal influenza vaccines. J Immunol 2014; 193: 469-75.

163. Fernandez CS, Kelleher, AD, Finlayson,R Godfrey DI, Kent SJ. NKT cell depletion in humans during early HIV-1 infection. Immunology and Cell Biology 2014; 92: 578-90.

162. Reece JC, Martyushev A, Petravic J, Grimm A, Gooneratne S, Amaresena T, De Rose R, Loh L, Davenport MP, Kent SJ. Measuring turnover of SIV DNA in resting CD4+ T cells using pyrosequencing: implications for the timing of HIV eradication therapies. Plos One 2014; 9: e93330.

161. Trist HM, Tan PS, Wines BD, Ramsland PA, Orlowski E, Stubbs J, Gardiner EE, Pietersz GA, Kent SJ, Stratov I, Burton DR, Hogarth PM. Polymorphisms and Interspecies Differences of the activating and inhibitory FcγRII of Macaque nemestrina Influence the Binding of Human IgG Subclasses. J Immunol 2014; 192: 792-803.

160. Parsons MS, Tang C-C, Jegaskanda S, Center RJ, Brooks AG, Stratov I, Kent SJ. Anti-human immunodeficiency virus antibody-dependent cellular cytotoxicity impairs natural killer cell NKp46 expression. J Immunol 2014; 192: 308-315.

159. Jegaskanda S, Amarasena T, Laurie KL, Tan H-X, Butler J, Parsons MS, Alcantara S, Petravic J, Davenport MP, Hurt A, Reading PC, Kent SJ. Standard trivalent influenza protein vaccination does not prime antibody-dependent cellular cytotoxicity (ADCC) in macaques. J Virol 2013; 87: 13706-18.

158. Lloyd SB, Kent SJ, Winnall WR. The high cost of fidelity. AIDS Research and Human Retroviruses 2014; 30: 8-16.

157. Kent SJ. Towards Improved Influenza vaccines (editorial). Journal of Infectious Diseases 2014; 209: 4-5.

156. De Rose R, Fernandez CS, Hedger MP, Kent SJ, Winnall WR. Characterisation of macaque testicular leukocyte populations and T-lymphocyte immunity. J Reproductive Immunology 2013; 100: 146-156.

155. Wren L, Stratov I, Kent SJ, Parsons MS. Obstacles to ideal anti-HIV antibody-dependent cellular cytotoxicity responses. Vaccine 2013; 47: 5506-17.

154. Kramski M, Parsons MS, Stratov I, Kent SJ. HIV-specific antibody immunity mediated through NK cells and monocytes. Current HIV Research. 2013; 11: 388-406.

153. Munier CM, Kelleher AD, Kent SJ, De Rose R. The role of T cell immunity in HIV infection. Current Opinion in Virology 2013; 3: 438-46.

152. Yu X, Fernandez CS, Alcantara S, Bailey M, De Rose R, Kelleher AD, Zaunders J, Kent SJ. Serial study of lymph node cell subsets using fine needle aspiration in pigtail macaques. J Immunol Methods 2013; 394: 73-83.

151. Lim CK, Yap MMC, Kent SJ, Batten CJ, De Rose R, Heng B, Brew B, Guillemin GJ. Characterization of the Kynurenine Pathway and Quinolinic Acid Production in Simian Macrophages. International Journal of Tryptophan Res 2013; 6: 7-19.

150. Fernandez CS, Jegaskanda S, Godfrey DI, Kent SJ. In-vivo stimulation of macaque NKT cells with α- Galactosylceramide. Clinical and Experimental Immunology 2013; 173: 480-92.

149. Cui J, De Rose R, Best JP, Johnston APR, Alcantara S, Liang K, Such GK, Kent SJ, Caruso F. Mechanically tunable, self-adjuvanting nanoengineered polypeptide particles. Advanced Materials 2013; 25: 3468-72 .

148. Jegaskanda S, Laurie K, Amarasena T, Winnall WR, Kramski M, De Rose R, Barr IG, Brooks A, Reading PC, Kent SJ. Age-associated cross-reactive ADCC toward 2009-pandemic influenza. Journal of Infectious Diseases 2013; 208:1051-61 .

147. Jegaskanda S, Weinfurter JT, Friedrich TC, Kent SJ. Antibody-dependent cellular cytotoxicity (ADCC) antibodies associated with control of pandemic H1N1 influenza infection of macaques. J Virol 2013; 87: 5512-22.

146. Kent SJ, Reece JC, Petravic J, Martyushev A, Kramski M, De Rose R, Cooper DA, Kelleher AD, Emery S, Cameron PU, Lewin SR, Davenport MP. The search for an HIV cure. Lancet ID 2013; 13: 614-21.

145. Major LD, Partridge TS, Gardner J, Kent SJ, De Rose R, Suhrbier A, Schroder WA. Induction of SerpinB2 and Th1/Th2 modulation by SerpinB2 during lentiviral infections in vivo. Plos One 2013; 8: e57343.

144. Reece JC, Alcantara S, Gooneratne S, Amarasena T, Fernandez CS, Laurie K, Hurt A, O'Connor S, Harris M, Petravic J, Martyushev A, Grimm A, Davenport MP, Stambas J, De Rose R, Kent SJ. Trivalent live attenuated Influenza-SIV vaccines: efficacy and evolution of CTL escape in macaques. J Virol 2013; 87: 4146-60.

143. Xu Y, Weatherall C, Bailey M, Alcantara S, De Rose R, Estaquier J, Wilson K, Suzuki K, Corbeil J, Cooper DA, Kent SJ, Kelleher AD, Zaunders J. SIV Infects Follicular Helper CD4 T cells in Lymphoid Tissues During Pathogenic Infection of Pigtail Macaques. J Virol 2013; 87: 3760-3773.

142. Madhavi V, Navis M, Chung AW, Isitman G, Wren LH, De Rose R, Kent SJ, Stratov I. Activation of NK cells by HIV-specific ADCC antibodies - role for granulocytes in presenting peptide epitopes. Human Vaccines and Immunotherapeutics 2013; 9: 1-9.

141. Parsons MS, Center RJ, Routy J-P, Rouleau D, LeBLanc R, Wainberg MA, Tremblay CL, Kent SJ, Bernard NF. Antibody responses to HIV Envelope from infections with multiple viral types and subtypes utilize the 1F7-idiotypic repertoire. AIDS Res Human Retro 2013; 29: 778-793.

140. Jegaskanda S, Job ER, Kramski M, Laurie K, Isitman G, De Rose R, Winnall WR, Stratov I, Brooks A, Reading PC, Kent SJ. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity (ADCC) antibodies in the absence of neutralizing antibodies. J Immunol 2013; 190: 1837-1848.

139. French MA, Center RJ, Wilson KM, Fleyfel I, Fernandez S, Schorcht A, Stratov I, Kramski M,Kent SJ, Kelleher AD . Isotype switched IgG antibodies to HIV Gag proteins may provide alternative or additional immune responses to 'protective' HLA-B alleles in HIV controllers. AIDS 2013; 27: 519-528.

138. Stratov I, Denholm J, Kent SJ. Azithromycin – more lethal than chloramphenicol? Sexual Health 2013; 10: 179-82.

137. Wren L, Chung A, Isitman G, Kelleher AD, Parsons MS, Amin J, Cooper DA, Stratov I, Navis M, Kent SJ. Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection. Immunology 2013; 138: 116-123

136. Madhavi V, Kent SJ, Stratov I.HIV-specific Antibody-Dependent Cellular Cytotoxicity: a Novel Vaccine Modality. Expert Review of Clinical Immunology 2012; 8: 767-74.

135. Kramski M, Schorcht A, Johnston APR, Lichtfuss G, De Rose R, Jegaskanda S, Stratov I, Kelleher AD, French MA, Center RJ, Jaworowski A, Kent SJ. Role of monocytes in mediating HIV-specific antibody-dependent cellular cytotoxicity. J Imm Methods 2012; 384: 51-61.

134. Fernandez CS, Cameron G, Godfrey I, Kent SJ. Ex-vivo alpha-Galactosylceramide activation of NKT cells in humans and macaques. J Imm Methods 2012; 382: 150-159.

133. Kramski M, Lichtfuss GF, Navis M, Isitman G, Wren L, Rawlin G, Center RJ, Jaworowski A, Kent SJ, Purcell DF. Anti-HIV antibody-dependent cellular cytotoxicity mediated by hyperimmune bovine colostrum IgG. Eur J Immunol 2012; 42: 2771-81.

132. Wren L, Parsons S, Isitman G, Center RJ, Kelleher AD, Stratov I, Bernard NF, Kent SJ. Influence of cytokines on HIV-specific antibody-dependent cellular cytotoxicity activation profile of natural killer cells. Plos One 2012; 7: e38580.

131. Winnall WR, Sexton A, Roath S, Alcantara S, De Rose R, Kent SJ. Characterisation of Simian Immunodeficiency Virus-infected cells in pigtail macaques. Virology 2012; 428: 11-20.

130. Jegaskanda S, Reece J, De Rose R, Stambas J, Sullivan L, Brooks AG, Kent SJ, Sexton A. Comparison of Influenza and SIV specific CD8 T cell responses in macaques. Plos One 2012; 7: e32431.

129. Kent SJ. Loss of control of HIV viremia associated with fat malabsorption drug orlistat. AIDS Res Human Retro 2012; 28: 961-2.

128. Mackay LK,  Stock AT, Ma JZ, Jones CM, Kent SJ, Mueller SN, Heath WR, Carbone F, Gephardt T. Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation. PNAS 2012; 109: 7037-7042.

127. Isitman G, Stratov I, Kent SJ. Antibody-Dependent Cellular Cytotoxicity and NK Cell-Driven Immune Escape in HIV Infection: Implications for HIV Vaccine Development. Advances in Virology 2012; e637208.

126. Parsons M, Wren L, Isitman G, Navis M, Stratov I, Bernard N, Kent SJ. HIV infection abrogates the functional advantage of natural killer cells educated through KIR3DL1/HLA-Bw4 interactions to mediate anti-HIV antibody-dependent cellular cytotoxicity. J Virol 2012; 86: 4488-95.

125. Reece J, Petravic J, Balamurali M, Loh L, Gooneratne S, De Rose R, Kent SJ, Davenport MP. An ''Escape Clock'' for Estimating the Turnover of SIV DNA in Resting CD4+ T Cells. Plos Pathogens 2012; 8: e1002615.

124. Chung AW, Navis M, Isitman G, Wren L, Silvers J, Amin J, Kent SJ, Stratov I. Activation of NK cells by ADCC antibodies and HIV disease progression. J AIDS 2011; 58: 127–131.

123. Queen SE, Mears BM, Kelly KM, Dorsey JL, Liao Z, Dinoso JB, Gama L, Adams J, Zink MC, Clements JE, Kent SJ, and Mankowski JL. Replication competent SIV Gag escape mutations archived in latent reservoirs during anti-retroviral treatment of SIV-infected macaques. J Virol 2011; 85: 9167-9175.

122. Pitisuttithum P, Rerks-Ngarm S, Chiu J, Kim J, Benenson M, Kent SJ, Tamashiro H, Marique A, Bernstein A, Goyal R, Ditangco RA, Cooper DA, Osmanov S, Mathieson B, Sandstrom E, Esparza J, Hoff R, Shao Y. Accelerating the development of an AIDS vaccine: the AIDS vaccine for Asia Network (Avan). Southeast Asian J Trop Med Public Health 2011; 42: 1130-46.

121. Johansson SE, Rollman E, Chung AW, Center RJ, Hejdeman B, Stratov I, Hinkula J, Wahren B, Kärre K, Kent SJ, Berg L. NK cell function and antibodies mediating ADCC in HIV-1 infected viremic and controller patients. Viral Immunology 2011; 24: 359-368.

120. Chung AW, Isitman G, Navis M, Kramski M, Center RC, Kent SJ, Stratov I. Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure. PNAS 2011; 108: 7505–10.

119. Fernandez CS, Reece JC, Saepuloh U, De Rose R, Ishkandriati D, O'Connor DH, Wiseman RW, Kent SJ. Screening and confirmatory testing of MHC class I alleles in pigtail macaques. Immunogenetics 2011; 63: 511-21.

118. Isitman G, Chung AW, Navis M, Kent SJ, Stratov I. Pol as a target for antibody dependent cellular cytotoxicity responses in HIV-1 infection. Virology 2011; 412: 110-6.

117. Chung AW, Navis M, Isitman G, Center R, Finlayson R, Bloch M, Gelgor L, Kelleher AD,Kent SJ, Stratov I. Activation of NK cells by ADCC responses during early HIV infection. Viral Immunology 2011; 24: 171-5.

116. Wren L, Kent SJ. HIV Vaccine efficacy trials - glimmers of hope and the potential role of antibody-dependent cellular cytotoxicity. Human Vaccines 2011; 7: 466-73.

115. Reece JR, Loh L, Alcantara S, Fernandez CS, Stambas J, Sexton A, De Rose R, Petravic J, Davenport MP, Kent SJ. Timing of immune escape linked to success or failure of vaccination. Plos One 2010; 5: e12774

114. Kent SJ, Cooper DA, Vun MC, Shao Y, Zhang L, Ganguly N, Bela B, Tamashiro H, Ditangco R, Rerks-Ngarm S, Pitisuttithum P, Kink NV, Bernstein A, Osmanov S. AIDS Vaccine for Asia Network (AVAN): Expanding the regional role in developing HIV vaccine. Plos Medicine 2010; 7: e1000331

113. Balamurali B, Petravic J, Loh L, Alcantara S, Kent SJ, Davenport MP. Does cytolysis by CD8+ T cells drive immune escape in SHIV infection? J Immunol 2010; 185: 5093-5101. (Highlighted by the editors in "In this issue").

112. Rerks-Ngarm S, Pitisuttithum P, Ganguly N, Zhang L, Tamashiro H, Cooper DA, Mean Chhi Vung, Bela B, Ditangco R, Nguyen Van Kinh, Bernstein A, Osmanov S, Mathieson B, Kent SJ, Shao Y. Defining the objectives of the AIDS vaccine for Asia network. Current Opinion in HIV/AIDS 2010; 5: 435-452

111. Isitman G, Navis M, Kent SJ, Stratov I. Designing immunity to HIV: Manipulating antibody-dependent cellular cytotoxicity antibodies. Future Medicine 2009; 3: 633-640.

110. Sexton A, Whitney PG, Chong SF, Zelikin AN, Johnston APR, De Rose R, Brooks AG, Caruso F, Kent SJ. A protective vaccine delivery system for in vivo T cell stimulation using nanoengineered polymer hydrogel capsules. ACS Nano 2009; 3: 3391-3400.

109. Center RJ, Wheatley AK, Campbell SM, Gaeguta AJ, Peut V, Alcantara S, Siebentritt C, Kent SJ, Purcell DFJ. Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens. Vaccine 2009; 27: 6605-6612.

108. Chong SF, Sexton A, De Rose R, Kent SJ, Zelikin AN, Caruso F. A paradigm for peptide vaccine delivery using viral epitopes encapsulated in degradable polymer hydrogel capsules. Biomaterials 2009; 30: 5178-5186.

107. Zaunders JJ, Munier ML, Seddiki N, Pett S, Ip S, Bailey M, Xu Y, Brown K, Dyer WB, Kim M, de Rose R, Kent SJ, Jiang L, Breit SN, Emery S, Cunningham AL, Cooper DA, Kelleher AD. High levels of human antigen-specific CD4+ T cells in peripheral blood revealed by stimulated co-expression of CD25 and CD134 (OX40). J Immunol 2009; 183: 2827-2836

106. Peut V, Campbell S, Gaeguta A, Center RJ, Wilson K, Alcantara S, Fernandez CS, Purcell DFJ, Kent SJ. Balancing reversion of CTL and neutralizing antibody escape mutations within HIV-1 Env upon transmission. J Virol 2009; 83: 8986-8992.

105. Chang J, Sitrivichayakul S, Avihingsanon A, Thompson AJV, Revill P, Iser D, Slavin J, Buranapraditkun S, Marks P, Matthews G, Cooper DA, Kent SJ, Cameron PU, Sasadeusz J, Desmond P, Locarnini S, Dore GJ, Ruxrungtham K, Lewin SR. Impaired qualityof the HBV-specific T cell response in HIV-1 HBV co-infection. J Viro 2009; 83: 7649-7658.

104. Sexton A, De Rose R, Reece JC, Alcantara S, Loh L, Moffat JM, Laurie K, Hurt A, Doherty PC, Turner SJ,Kent SJ, Stambas J. Evaluation of recombinant Influenza-SIV vaccines in macaques. J Virol 2009; 83: 7619-7628.

103. Alcantara S, Reece JC, Amarasena T, De Rose R, Manitta J, Amin J, Kent SJ. Thrombocytopenia is strongly associated with simian AIDS in pigtail macaques. J AIDS 2009; 51: 374-379.

102. Mason RD, De Rose R, Kent SJ. Differential patterns of immune escape at Tat-specific cytotoxic T cell epitopes in pigtail macaques. Virology 2009; 388: 315-323.

101. Loh L, Reece JC, Fernandez CS, Alcantara S, Center R, Howard J, Purcell DFJ, Balamurali M, Petravic J, Davenport MP,Kent SJ. Complexity of the inoculum determines the rate of reversion of SIV Gag CD8 T cell mutant virus and outcome of infection.PloS Pathogens 2009; 5(4): e1000378.

100. Fernandez CS, Chan AC, Kyparissoudis K, De Rose R, Godfrey DI,Kent SJ. Peripheral NKT cells in SIV-infected macaques. Journal of Virology 2009; 83: 1617-1624.

99. Chung AW, Rollman E, Center RJ, Kent SJ, Stratov I. Rapid degranulation of NK cells following activation by HIV-specific antibodies. Journal of Immunology 2009; 182: 1202-1210.

98. Peut V, Kent SJ. Substantial Envelope-specific CD8 T cell immunity fails to control SIV. Virology 2009; 384: 21-27.

97. Mason RD, Alcantara S, Peut V, Loh L, Lifson JD, De Rose R, Kent SJ. Inactivated SIV-pulsed autologous fresh blood cells as an immunotherapy strategy. Journal of Virology 2009; 83: 1501-1510.

96. De Rose R, Mason RD, Loh L, Peut V, Smith MZ, Fernandez CS, Alcantara S, Amarasena T, Reece J, Seddiki N, Kelleher AD, Zaunders J, Kent SJ. Safety, immunogenicity and efficacy of peptide-pulsed cellular immunotherapy in macaques. Journal of Medical Primatology 2008; 37 (Supp 2): 69-78.

95. Mankowski JL, Queen SE, Fernandez CS, Tarwater PM, Karper JM, Adams RJ, Kent SJ. Natural Host Genetic Resistance to Lentiviral CNS disease: A Neuroprotective MHC Class I Allele to SIV-infected Macaques. PloS ONE 2008; 3(11): e3603. doi:10.1371/journal.pone.0003603.

94. De Rose R, Zelikin A, Johnston APR, Sexton A, Chong SF, Cortez C, Mulholland W, Caruso F, Kent SJ. Binding, Internalisation and Antigen Presentation of Vaccine-Loaded Nanoengineered Capsules in Blood. Advanced Materials 2008; 20: 4698-4703.

93. Chung A, Rollman E, Johansson S, Kent SJ, Stratov I. The Utility of ADCC responses in HIV infection. Current HIV Research 2008; 6: 515-519.

92. Davenport MP, Loh L, Petravic J, Kent SJ. Rates of HIV immune escape and reversion in HIV: Implications for viral evolution and vaccination. Trends in Microbiology 2008; 16: 561-566.

91. Mason RD, De Rose R, Seddiki N, Kelleher AD, Kent SJ. Low pre-infection levels and loss of central memory CD4+ T cells may predict rapid progression in SIV-infected pigtail macaques. Virology 2008; 381: 11-15.

90. Rollman E, Mason RD, Lin J, Brooks AG, Kent SJ. Protection afforded by live attenuated SIV is associated with rapid killing kinetics of CTLs. Journal of Medical Primatology 2008; 37 (Supp 2): 24-32.

89. De Rose R, Fernandez CS, Loh L, Peut V, Mason RD, Alcantara S, Reece J, Kent SJ. Delivery of immunotherapy with peptide-pulsed blood in macaques. Virology 2008; 378: 201-204.

88. Smith MZ, Asher TE, Venturi V, Davenport MP, Douek DC, Price DA, Kent SJ. Limited maintenance of vaccine-induced SIV-specific CD8 T cell receptor clonotypes after virus challenge. J Virol 2008; 82: 7357-7368.

87. De Rose R, Fernandez CS, Smith MZ, Batten CJ, Alcantara S, Peut V, Rollman E, Loh L, Mason RD, Wilson K, Law MG, Handley AJ, Kent SJ. Control of Viremia and Prevention of AIDS following Immunotherapy of SIV-Infected Macaques with Peptide-Pulsed Blood. PloS Pathogens 2008; 4(5): e1000055. doi:10.1371/journal.ppat.1000055.

86. Rollman E, Turner SJ, Kedzierska K, Kent SJ. Anti-SIV cytolytic molecules in pigtail macaques. AIDS Research and Human Retroviruses 2008; 24: 1127-1131.

85. Loh L, Kent SJ. Quantification of Simian Immunodeficiency Virus Cytotoxic T Lymhocyte Escape Mutant Viruses. AIDS Research and Human Retroviruses 2008; 24: 1067-1072.

84. Stratov I, Chung A, Kent SJ. Robust NK-cell mediated HIV-specific antibody-dependent responses in HIV-infected subjects. J  Virol 2008; 82: 5450-5459.

83. Mason RD, De Rose R, Kent SJ. CD4+ T cell subsets: what really counts in preventing HIV disease? Expert Review of Vaccines 2008; 7: 155-158.

82. Petravic J , Loh L, Kent SJ, Davenport MP. CD4+ Target cell availability determines the dynamics of immune escape and reversion in vivo. J Virol 2008; 82: 4091-4101.

81. Kent SJ, De Rose R, Mokhonov VV, Mokhonova EI, Fernandez CS, Alcantara S, Rollman E, Mason RD, Loh L, Peut V, Reece JC, Wang XJ, Wilson KM, Suhrbier A, Khromykh A. Evaluation of recombinant Kunjin replicon SIV vaccines for protective efficacy in macaques. Virology 2008; 374: 528-534.

80. Woollard DJ, Haqshenas G, Dong X, Pratt BF, Kent SJ, Gowans EJ. Virus-Specific T-Cell Immunity Correlates with Control of GB Virus Type B Infection in Marmosets. J Virol 2008; 82: 3054-3060.

79. Loh L, Petravic J, Batten CJ, Davenport MP, Kent SJ. Vaccination and timing influence SIV immune escape viral dynamics in vivo. PloS Pathogens 2008; 4(1): e12 doi:10.1371/journal.ppat.0040012.

78. Chang JJ, Thompson A, Visvanathan K, Kent SJ, Cameron PU, Wightman F, Bowden S, Desmond P, Locarnini SA, Lewin SR. Th1/Th2 imbalance of Hepatitis B Virus (HBV)-specific T-cells in the liver of chronic HBV patients associated with liver damage without viral clearance. Hepatology 2007; 46: 1332-1340.

77. Peut V, Kent SJ. Utility of HIV-1 Envelope as a T Cell Immunogen. J Virol 2007; 81: 13125-13134.

76. Rollman E, Smith MZ, Brooks A,  Purcell DFJ, Zuber B, Ramshaw IA, Kent SJ. Killing kinetics of SIV-specific CD8+ T cells: implications for HIV vaccine strategies. Journal of  Immunology 2007; 179: 4571-4579.

75. Fernandez C , Smith M, Batten C, De Rose R, Reece J, Rollman E, Venturi V, Davenport M, Kent SJ. Vaccine-induced T cells control reversion of AIDS virus immune escape mutants. J Virol 2007; 81: 4137-4144.

74. Shehu-Xhilaga M, Kent SJ, Batten CJ, Ellis S, Van der Meulen J, O'Bryan M, Cameron PU, Lewin SR, Hedger MP. The testis and epididymis are productively infected by SIV and SHIV in juvenile macaques during the post-acute stage of infection. Retrovirology 2007; 4:7.

73. Kent SJ, De Rose R, Rollman E. Drug evaluation: DNA/MVA prime-boost HIV vaccine. Current Opinion in Investigational Drugs 2007; 8:159-167.

72. Loh L, Batten CJ, Petravic J, Davenport MP, Kent SJ. In vivo fitness costs of different Gag CD8 T cell escape mutant simian-human immunodeficiency viruses in macaques. J Virol 2007; 81: 5418-22. View supplementary tables .

71. De Rose R, Batten CJ, Smith MZ, Fernandez CS, Peut V, Thomson S, Ramshaw IA, Coupar BE, Boyle DB, Venturi V, Davenport MP, Kent SJ. Comparative efficacy of subtype AE simian-human immunodeficiency virus priming and boosting vaccines in pigtail macaques. J Virol 2007; 81: 292-300.

70. Pratt BF, O'Connor DH, Lafont BAP, Mankowski JL, Fernandez CS, Triastuti R, Brooks AG, Kent SJ, Smith MZ. MHC class I allele frequencies in pigtail macaques of diverse origin. Immunogenetics 2006; 58: 995-1001.

69. De Rose, R, Sullivan MT, Dale CJ, Kelleher AD, Emery, S, Cooper DA, Ramshaw IA, Boyle DB, Kent SJ. Dose-response relationship of DNA and recombinant fowlpox virus prime-boost HIV vaccines. Human Vaccines 2006; 2: 134-136.

68. Zaunders J, Dyer WB, Munier ML, Ip S, Liu J, Amyes E, Rawlinson B, De Rose R, Kent SJ, Sullivan JS, Cooper DA, Kelleher AD. D127+ CCR5+ CD38+++ CD4+ Th1 effector cells are an early component of the primary immune response to vaccinia and precede IL-2+ memory CD4+ T cells. J Virol 2006; 80: 10151-10161.

67. Kelleher A, Puls R, Bebbington M, Boyle DB, Ffrench RA, Kent SJ, Law MG, Purcell DFJ, Ramshaw IA, Cooper DA, Emery S. A randomised, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. AIDS 2006; 20: 294-297.

66. Stratov I, Dale CJ Chea S, Montefiori DC, De Rose R, Reece JC,Kent SJ. Characteristics of effective immune control of Simian/Human Immunodeficiency Virus in pigtail macaques. AIDS Research and Human Retroviruses 2006; 22: 27-32.

65. Batten CJ, De Rose R, Wilson KM, Agy MB, Chea S, Stratov I, Montefiori DC, Kent SJ. Comparative evaluation of simian, simian-human, and human Immunodeficiency virus infection in the pigtail macaque (Macaca nemestrina) model. AIDS Research and Human Retroviruses 2006; 22: 580-588.

64. Peut V, Kent SJ. Fitness constraints on immune escape from HIV: Implications of Envelope as a target for both HIV-specific T cells and antibody. Current HIV Research 2006; 4: 191-7.

63. Coupar BE, Purcell DF, Thomson SA, Ramshaw IA,Kent SJ, Boyle DB. Fowlpox virus vaccines for HIV and SHIV clinical and pre-clinical trials. Vaccine 2006; 24: 1378-88.

62. Smith MZ, Fernandez CS, Chung A, Dale CJ, De Rose R, Lin J, Brooks AG, Krebs KC, Watkins DI, O'Connor DH, Davenport MP, Kent SJ. The pigtail macaque MHC class I allele Mane-A*10 presents an immundominant SIV Gag epitope: identification, tetramer development and implications of immune escape and reversion. J Med Primatol 2005; 34: 282-93.

61. Kent SJ, Dale CJ, Ranasinghe C, Stratov I, De Rose R, Chea S, Montefiori DC, Thomson S, Ramshaw IA, Coupar BEH, Boyle DB, Law M, Wilson KM, Ramsay AJ. Mucosally-administered Human-Simian Immunodeficiency Virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3. Vaccine 2005; 23: 5009-21.

60. Thomson SA, Jaramillo AB, Shoobridge M, Dunstan KJ, Everett B, Ranasinghe C, Kent SJ, Medveckzy C, Ffrench RA, Ramshaw IA. Development of a Synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use. Vaccine 2005; 23: 4647-57.

59. Kent SJ, Fernandez CS, Dale CJ, Davenport MP. Reversion of immune escape HIV variants upon transmission: insights into effective viral immunity. Trends in Microbiology 2005; 13: 243-6.

58. Stratov I, Dale CJ, Chea S, McCluskey J, Kent SJ. Induction of T-cell immunity to antiretroviral drug-resistant HIV-1. Journal of Virology 2005; 79: 7728-39.

57. Fernandez CS, Stratov I, De Rose R, Walsh K, Dale CJ, Smith MZ, Agy MB, Hu S-L, Krebs K, Watkins DI, O'Connor DH, Davenport MP, Kent SJ. Rapid viral escape at an immunodominant SHIV CTL epitope exacts a dramatic fitness cost. Journal of Virology 2005; 79: 5721-31.

56. Stratov I, Dale CJ, Kent SJ. Phenotypic and kinetic analysis of effective Simian-Human Immunodeficiency Virus-specific T-cell responses in DNA and Fowlpoxvirus vaccinated macaques. Virology 2005; 337: 222-234.

55. De Rose R, Taylor EL, Law M, Van der Meide PH, Kent SJ. Granulocyte contamination dramatically inhibits spot formation in AIDS virus-specific ELISpot assays: analysis and strategies to ameliorate. Journal of Immunological Methods 2005; 279: 177-86.

54. Pamungkas J, De Rose R, Iskandriati D, Noviana R, Paramastri Y, Dale CJ, Shoobridge M, Medveczky CJ, Ramshaw IA, Thomson SA, Kent SJ. Comparison of whole gene and whole virus scrambled antigen approaches for DNA prime and Fowlpoxvirus boost HIV-1 vaccine regimens in macaques. AIDS Research and Human Retroviruses 2005; 21: 292-300.

53. Dale CJ, Thomson S, De Rose R, Ranasinghe C, Medveczky CJ, Pamungkas J, Boyle DB, Ramshaw IA, Kent SJ. Prime boost strategies in DNA Vaccines. In: DNA Vaccines , 2nd edition Ed: M Salzman; Humana Press 2006: 171-198.

52. Chang JJ, Wightman F, Bartholomeusz A, Ayres A, Kent SJ, Sasadeusz J, Lewin SR.  Reduced HBV-specific T-cell responses in HIV-1-HBV co-infected individuals receiving HBV-active antiretroviral therapy. Journal of Virology 2005; 79: 3038-51.

51. Chea S, Dale CJ, De Rose R, Ramshaw IA, Kent SJ. Enhanced cellular immunity in macaques following a novel peptide immunotherapy. Journal of Virology 2005: 79; 3748-3757.

50. Smith MZ, Kent SJ. Genetic influences on HIV infection: implications for vaccine development. Sexual Health 2005: 2; 53-62.

49. De Rose R, Chea S, Dale CJ, Reece J, Fernandez CS, Wilson KM, Thomson S, Ramshaw IA, Coupar BEH, Boyle DB, Sullivan MT, Kent SJ. Subtype AE HIV-1 DNA and recombinant Fowlpoxvirus vaccines encoding 5 shared HIV-1 genes: safety and T cell immunogenicity in macaques. Vaccine 2005: 23; 1949-1956.

48. Dale CJ, De Rose R, Stratov I, Chea S, Montefiori D, Thomson S, Ramshaw IA, Coupar BEH, Boyle DB, Law M, Kent SJ. Efficacy of DNA and Fowlpoxvirus prime/boost vaccines for SHIV. Journal of Virology 2004; 78: 13819-13828.

47. Smith MZ, Dale CJ, De Rose R, Stratov I, Fernandez CS, Brooks AG, Weinfurter J, Krebs K, Riek C, Watkins DI, O'Connor DH, Kent SJ. Analysis of Pigtail Macaque Major Histocompatibility Complex Class I Molecules Presenting Immunodominant Simian Immunodeficiency Virus Epitopes. Journal of Virology 2005; 79: 684-695.

46. Dale CJ, De Rose R, Wilson KM, Croom HA, Thomson S, Coupar BEH, Ramsay A, Purcell DFJ, Ffrench R, Law M, Emery S, Cooper DA, Ramshaw IA, Boyle DB, Kent SJ. Evaluation of HIV-1 DNA vaccines optimized for primate CpG content and fowlpoxvirus vaccines co-expressing IFNg or IL-12. Vaccine 2004; 23: 188-197.

45. Stratov I, DeRose R, Purcell DFJ, Kent SJ. Vaccines and vaccine strategies against HIV. Current Drug Targets, 2004; 5: 71-88.

44. Thompson KA, Kent SJ, Gahan ME, Purcell DFJ, McLean CA, Preiss S, Dale CJ, Wesselingh SL. Neurotropism of nef/LTR deleted Simian Immunodeficiency Virus. J Neurovirol 2003; 9: 442-451.

43. Dale CJ, Liu XS, De Rose R, Purcell DFJ, Anderson J, Xu Y, Leggatt GR, Frazer IH, Kent SJ. Chimeric human papilloma virus – simian/human immunodeficiency virus virus-like-particle vaccines: immunogenicity and protective efficacy in macaques. Virology 2002; 301: 176-87.

42. Corbett AJ, McKenzie BS, Sutherland RM, Brady JL, Strugnell RA,Kent SJ, Kramer DR, Boyle JS, Pearse MJ and Lew, AM (2002) The utility of immunoglobulin fusions in DNA vaccines In: The Antibodies, Vol 7 pp29-42. Ed M Zanetti & JD Capra, Taylor & Francis, London.

41. Kent SJ, Dale CJ, Mijch AM. Knowledge and commitment for action. The 14th International AIDS Conference, Barcelona, July 2002. Medical Journal of Australia 2002; 177: 587-9.

40. Kent SJ. Vaccines for HIV in the developing world. Internal Medicine Journal 2002; 32: 136-7.

39. Kent SJ, Dale CJ, Preiss S, Purcell DFJ. Evidence of recombination between 3' and 5' LTRs in macaques inoculated with SIV DNA. AIDS Research and Human Retroviruses 2002; 18: 227-30.

38. Kent SJ, Dale CJ, Preiss S, Mills J, Campagna D, Purcell DFJ. Vaccination with attenuated simian immunodeficiency virus by DNA inoculation. J Virol 2001; 75: 11930-4.

37. Kent SJ, Ada GL, Hayes E, Lewis IM. Determining the immune mechanisms of protection from AIDS: correlates of immunity and the development of syngeneic macaques. Immunological Reviews 2001; 183: 94-108.

36. McKenzie BS, Corbett AJ, Brady JL, Dyer CM, Strugnell RA,Kent SJ, Kramer DR, Boyle JS, Lew AM. Enhancing nucleic acid vaccines: task and tactics. Immunologic research 2001; 24: 225-44.

35. Kent SJ, Cameron PU, Reece J, Thompson P, Purcell DFJ. Attenuated and wild type HIV-1 infections and Long Terminal Repeat mediated gene expression from plasmids delivered by gene gun to human skin ex vivo and macaques in vivo. Virology 2001; 287: 71-8.

34. Purcell DFJ, Cameron PU, Mills J,Kent SJ. Infectivity of wild-type and deleted proviral SIV DNA. Developments in Biologicals 2001; 106: 395-406.

33. Joy AK, Vogelnest L, Middleton DJ, Dale CJ, Campagna D, Purcell DFJ, Kent SJ. SIV infections in vervet monkeys (Clorocebus aethiops) at an Australian zoo. Aust Veterinary Journal 2001; 79: 406-8.

32. Kent SJ. Vaccines to prevent HIV and AIDS. Microbiology Australia 2001; 22: 12-15.

31. Sands AR, Kent SJ, Dax EM, Johnson EM. Antibody responses to an HIV-1 vaccine. Proceedings of the 6th European Conference on Experimental AIDS Research. Monduzzi Ed, Bologna, Italy, 2001: 75-80.

30. Kent SJ, Zhao A, Dale CJ, Land S, Boyle DB, Ramshaw IA. A recombinant avipox HIV-1 vaccine expressing interferon-gamma is safe and immunogenic in macaques. Vaccine 2000; 18: 2250-6.

29. Dale CJ, Zhao A, Jones SL, Boyle DB, Ramshaw IA, Kent SJ. Induction of T-helper type 1 responses following therapeutic vaccination of macaques with a recombinant fowlpoxvirus HIV-1 vaccine co-expressing interferon-gamma. J Med Primatol 2000; 29: 240-7.

28. Dale CJ, Kent SJ. Vaccines for HIV. Expert Opinion on Therapeutic patents 2000; 10: 1179-88.

27. Ramsay AJ, Kent SJ, Strugnell RA, Suhrbier A, Thomson SA, Ramshaw IA. Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity. Immunological Reviews 1999; 171: 27-44.

26. Kent SJ. HIV vaccines – promise and directions. Medical Journal of Australia 1999; 171: 124-5.

25. Kent SJ. Vaccination for HIV infected individuals. Position paper of the Australasian Society for HIV medicine, 1999.

24. Kent SJ, Zhao A, Best S, Chandler JD, Boyle D, Ramshaw IA. Enhanced T cell immunogenicity and protective efficacy of a HIV-1 vaccine regimen consisting of consecutive DNA priming and recombinant fowlpox virus boosting. Journal of Virology 1998; 72: 10180-8.

23. Joy AK, Dale CJ, Kent SJ. Can HIV be prevented by a vaccine? Drugs R & D 1999; 1: 431-40.

22. Kent SJ, Lewis IM. Primate Syngeneic modelling systems for HIV vaccines. Reproduction Fertil Dev 1998; 10: 651-7.

21. Kent SJ. Preventive HIV-1 vaccines: Where are we going? Int. J. of STD and AIDS 1998; 9: 715-9.

20. Kent SJ. Antiviral CD4 cell response in simian immunodeficiency virus infected macaques. Journal of Infectious Diseases 1998; 177: 1771-2.

19. Cardinal B, Kent SJ. Behavioural effects of simple manipulable environmental enrichment techniques on macaques. Laboratory Primate Newsletter 1998; 37: 1-4.

18. Looney DJ, MacClure J, Kent SJ, Radaelli A, Kraus G, Schmidt A, Steffy K, Greenberg P, Hu S-L, Morton W, Wong-Staal F. A minimally replicative HIV-2 live-virus vaccine protects M nemestrina from disease after HIV-2287 challenge. Virology 1998; 242: 150-60.

17. Kent SJ, Woodward A, Zhao A. HIV-1 specific T cell responses correlate with control of acute HIV-1 infection in macaques. Journal of Infectious Diseases 1997; 176: 1188-97.

16. Mills J, Deacon N, McPhee D, Learmont J, Crowe SM, Greenway A, Rhodes D, Oelrichs R, Kent SJ, Geczy A, Sullivan J. Effects of 13-17 years of infection with a nef-deleted strain of HIV: the Sydney Blood Bank Cohort. in: Colloque Des Cent Gardes: Retroviruses of Human AIDS and Related Animal Diseases. Eds Girard M and Dodet B. 1997 p293-9.

15. Kent SJ, Greenberg PD, Hoffman MC, Akridge R, McElrath MJ. Antagonism of vaccine-induced CD4+ CTL by primary HIV-1 infection: potential mechanism of vaccine failure. Journal of Immunology 1997; 158: 807-15.

14. Dyer WB, Geczy AF, Kent SJ, McIntyre LB, Blasdall SA, Learmont JC, Sullivan JS. Lymphoproliferative immune function in the Sydney Blood Bank Cohort, infected with natural nef/long terminal repeat mutants, and in other long-term survivors of transfusion-acquired HIV-1 infection. AIDS, 1997; 11: 1565-74.

13. Kent SJ, Hu S-L, Corey L, Morton WR, Greenberg PD. Detection of SIV-specific CD8+ T cells in Macaques protected from SIV challenge by prior subunit vaccination. Journal of Virology 1996; 70: 4941-9.

12. Kent SJ, Clancy R, Ada GL. Prospects for a preventative HIV vaccine. Medical Journal of Australia, 1996; 165: 212-5.

11. Kent SJ, Corey L, Agy M, Morton WR, McElrath MJ, Greenberg PD. Cytotoxic and proliferative T cell responses in HIV-1 infected M nemestrina. Journal of Clinical Investigation 1995; 95: 248-56.

10. Biggs BA, Hewish M,Kent SJ, Hayes K, Crowe SM. HIV infection of human monocyte derived macrophages impairs ingestion and killing of Toxoplasma gondii. Journal of Immunology 1995; 154: 6132-9.

9. Kent SJ, Stallard V, Corey L, Hu S-L, Morton WR, Gritz L, Panacali D, Greenberg PD. Analysis of SIV-specific CTL responses in SIV infected macaques using antigen specific stimulations with recombinant vaccinia and fowlpox viruses. AIDS Research and Human Retroviruses 1994; 5: 551-60.

8. Kent SJ, Stent G, Sonza S, Hunter SD, Crowe SM. HIV-1 Infection of Monocyte-derived Macrophages Reduces Fc and Complement Receptor Expression. Clinical and Experimental Immunology 1994; 95: 450-4.

7. Crowe SM, Vardaxis N,Kent SJ, Maerz A, Hewish MJ, McGrath MS, Mills J. HIV-1 infection of monocyte-derived macrophages in vitro reduces phagocytosis of Candida albicans. Journal of Leukocyte Biology 1994; 56: 318-27.

6. Swanson CE, Tindall B, Cooper DA for the Australian Zidovudine Study Group* (Kent SJ, member of study group) Efficacy of zidovudine treatment in homosexual men with ARC. AIDS 1994; 8: 625-34.

5. Kent SJ, Van Scoy MS, Skerrett S. Listeria peritonitis with review of the literature. Aust N Z J Med 1994; 24: 405.

4. Kent SJ, Crowe SM, Yung A, Lucas CR, Mijch AM. Tuberculous meningitis - A 30 year review. Clinical Infectious Diseases 1993; 17: 987-94.

3. Slavin MA, Hoy JF, Stewart K, Pettinger MB, Lucas CR, Kent SJ. Oral dapsone versus nebulized pentamidine for Pneumocystis carinii pneumonia prophylaxis: an open randomized prospective trial to assess efficacy and haematological toxicity. AIDS 1992; 6: 1169-74.

2. Kent SJ, Hoy JF. Prevention of Meningoccal infections. Current Therapeutics 1992; 33: 43-46.

1. Fairley CK ,Kent SJ, Street A, Mijch A, Hoy JF. Invasive aspergillosis in AIDS. Aust N Z J Med 1991; 21: 747-9.